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To my North Star(s)

  
POPULAR SCIENTIFIC SUMMARY 
Microbes are living organisms that require a microscope to be seen, with sizes ranging from 
0.1 micrometers to a few millimeters. Most of them have a single cell (the smallest unit of 
life), where a membrane encloses a compartment that contains the basic molecules to sustain 
life. Humans and microbes have always had a secret partnership, since they are essential in 
food (e.g. bread) and drink (e.g. wine) production. However, our knowledge of their existence 
only came in the late 1600s.  
The work in this thesis was performed on a subset of microbes called bacteria. Bacteria are 
everywhere around us; in the air we breathe, in the water we drink, in the food we eat and 
inside our bodies. In fact, the number of bacteria residing in our bodies is ten times greater 
than the number of our own cells. Some bacteria are beneficial for us, while others are 
responsible for a variety of diseases. The drugs used for the treatment of bacterial infections 
are called antibiotics. 
In the first paper, we developed a mathematical model that can explain why bacteria keep 
dying after removal of the antibiotic, how does the number of bacteria affect a possible 
treatment with antibiotics and how do persistent bacteria arise. Persistent are those bacteria 
that do not respond to antibiotic treatment. The model describes the reaction between the 
antibiotic and the target molecules and thus the resulting effect on bacterial survival. It could 
be used in the design of optimal antibiotic treatment strategies. 
In the second paper we focused on Staphylococcus aureus, a bacterium responsible for 
multiple pathological conditions. Using six different antibiotics currently used in the clinic, 
we showed that older cultures are harder to kill by antibiotics and tried to provide a rational 
explanation as to why this happens. Our findings suggest that there is an increasing number 
of persister cells in aging cultures, directly affecting the number of bacteria surviving 
treatment. 
Some bacteria require oxygen to survive, while some do not. A number of bacteria can 
survive in both conditions but their characteristics change in the presence or absence of 
oxygen. In the third paper, we used a Staphylococcus aureus that is resistant to one of the 
most commonly used antibiotics and tried to explain why antibiotic treatment does not have 
the same effect at different oxygen levels.  
The majority of bacteria on the human body live inside our gastrointestinal tract. It is well 
accepted that our gut bacteria can communicate through chemical signals with our brain. In 
the last paper we provide evidence of a novel signaling pathway mediating the 
communication of the gut-residing bacteria and the developing brain. 
Overall, bacteria have a profound effect on human health and disease. In this thesis I tried to 
shed light in some elements that govern the interaction between antibiotics and bacteria. I 
hope my contribution will spark the interest of future researchers that will expand this 
knowledge and provide the means for more effective antibiotic treatment. 
  
ΕΠΙΣΤΗΜΟΝΙΚΗ ΠΕΡΙΛΗΨΗ 
Οι µικροοργανισµοί είναι µορφές ζωής ορατές µόνο µε µικροσκόπιο, µε µεγέθη που 
κυµαίνονται από 0.1 µικρόµετρα έως µερικά χιλιοστά. Οι περισσότεροι από αυτούς έχουν 
ένα µόνο κύτταρο (η βασική µονάδα της ζωής), όπου µια µεµβράνη περικλείει ένα 
διαµέρισµα που περιέχει τα βασικά µόρια για τη συντηρήση τη ζωής. Οι άνθρωποι και οι 
µικροοργανισµοί είχαν πάντα µια µυστική συνεργασία, αφού είναι απαραίτητοι για την 
παραγωγή τροφίµων (π.χ. ψωµί) και ποτών (π.χ. κρασί). Ωστόσο, η ύπαρξή τους µας έγινε 
γνωστή µόνο στα τέλη του 16ου αιώνα. 
Η διατριβή αυτή πραγµατοποιήθηκε σε ένα υποσύνολο µικροοργανισµών που ονοµάζονται 
βακτήρια. Τα βακτήρια είναι παντού γύρω µας: στον αέρα που αναπνέουµε, στο νερό που 
πίνουµε, στο φαγητό που τρώµε και στο σώµα µας. Στην πραγµατικότητα, ο αριθµός των 
βακτηρίων στο σώµα µας είναι δέκα φορές µεγαλύτερος από τον αριθµό των κυττάρων µας. 
Ορισµένα βακτήρια είναι ευεργετικά για εµάς, ενώ άλλα είναι υπεύθυνα για µια ποικιλία 
ασθενειών. Τα φάρµακα που χρησιµοποιούνται για τη θεραπεία βακτηριακών λοιµώξεων 
ονοµάζονται αντιβιοτικά. 
Στην πρώτη εργασία αναπτύξαµε ένα µαθηµατικό µοντέλο που µπορεί να εξηγήσει γιατί τα 
βακτήρια συνεχίζουν να πεθαίνουν µετά την αποµάκρυνση του αντιβιοτικού, πώς ο αριθµός 
των βακτηρίων επηρεάζει µια πιθανή θεραπεία και πώς προκύπτουν τα επίµονα βακτήρια. 
Επίµονα θεωρούνται τα βακτήρια που δεν ανταποκρίνονται στη θεραπεία µε αντιβιοτικά. Το 
µοντέλο περιγράφει την αντίδραση µεταξύ του αντιβιοτικού και των µορίων στόχων και 
συνεπώς το αποτέλεσµα που έχει στην επιβίωση των βακτηρίων. Θα µπορούσε να 
χρησιµοποιηθεί στο σχεδιασµό βέλτιστων στρατηγικών αντιβιοτικής θεραπείας. 
Στη δεύτερη εργασία επικεντρώθηκα στον Σταφυλόκοκκο, ένα βακτήριο υπεύθυνο για 
πολλές παθολογικές καταστάσεις. Χρησιµοποιώντας έξι διαφορετικά αντιβιοτικά που 
χρησιµοποιούνται σήµερα στην κλινική, δείξαµε ότι οι γηραιότερες καλλιέργειες είναι πιο 
δύσκολο να σκοτωθούν µε αντιβιοτικά και προσπαθήσαµε να δώσουµε µια λογική εξήγηση 
για αυτό το φαινόµενο. Τα ευρήµατά µας υποδεικνύουν ότι υπάρχει ένας αυξανόµενος 
αριθµός επίµονων κυττάρων σε γηραιότερες καλλιέργειες, επηρεάζοντας αρνητικά µια 
πιθανή θεραπευτική αγωγή µε αντιβιοτικά. 
Ορισµένα βακτήρια απαιτούν οξυγόνο για να επιβιώσουν, ενώ κάποια άλλα όχι. Μερικά 
βακτήρια µπορούν να επιβιώσουν και στις δύο συνθήκες αλλά τα χαρακτηριστικά τους 
αλλάζουν µε την παρουσία ή απουσία οξυγόνου. Στην τρίτη εργασία χρησιµοποιήσαµε ένα 
Σταφυλόκοκκο ανθεκτικό σε ένα από τα πλέον χρησιµοποιούµενα αντιβιοτικά και 
προσπαθήσαµε να εξηγήσουµε γιατί η θεραπευτική αγωγή µε άλλα αντιβιοτικά δεν έχει το 
ίδιο αποτέλεσµα σε διαφορετικά επίπεδα οξυγόνου. 
Η πλειοψηφία των βακτηρίων που ζουν στο ανθρώπινο σώµα βρίσκονται µέσα στο 
γαστρεντερικό µας σύστηµα. Είναι πλέον αποδεδειγµένο ότι τα βακτήρια του εντέρου 
µπορούν να επικοινωνούν µέσω χηµικών σηµάτων µε τον εγκέφαλό µας. Στην τελευταία 
  
 εργασία, παρέχουµε στοιχεία για ένα νέο µονοπάτι σηµατοδότησης που µεσολαβεί στην 
επικοινωνία των βακτηρίων που διαµένουν στο έντερο και του αναπτυσσόµενου εγκεφάλου. 
Συνολικά, τα βακτήρια έχουν σηµαντική επίδραση στην ανθρώπινη υγεία. Σε αυτή τη 
διδακτορική διατριβή προσπάθησα να ρίξω φως σε ορισµένα στοιχεία που διέπουν την 
αλληλεπίδραση µεταξύ αντιβιοτικών και βακτηρίων. Ελπίζω ότι η συµβολή µου θα 
προκαλέσει το ενδιαφέρον µελλοντικών ερευνητών που θα επεκτείνουν αυτή τη γνώση και 
θα παράσχουν τα µέσα για πιο αποτελεσµατικές θεραπευτικές αγωγές µε αντιβιοτικά. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ABSTRACT 
The pathological outcome of a bacterial infection depends on the interplay among the host’s 
innate defenses, the virulence arsenal of the pathogen and antibiotic treatment strategies. 
Understanding this interplay will provide mechanistic insights on antibiotic 
pharmacodynamics and bacterial pathogenesis, and set the stage for the development of novel 
therapeutic interventions.  
The discovery and subsequent mass production of antibiotics has been one of the greatest 
achievements in medical history. Regardless of the fact that antibiotics have been used in 
medicine for more than 70 years, there is no clear mechanistic understanding of their effect 
on microbial populations in the host, and prediction of antibiotic pharmacodynamics is still 
complicated. In Paper I, we aimed to develop a simple model that links bacterial population 
biology and classical reaction kinetics, while rationally explaining complex patterns of 
antibiotic action (post-antibiotic growth suppression, density-dependent antibiotic effects, and 
persister cell formation). 
The emergence of antibiotic resistance along with the decline in the rate of discovery of new 
antibiotics has been one the major challenges in modern medicine. Multi-resistant strains (eg. 
methicillin resistant Staphylococcus aureus, MRSA) are responsible for infections with poor 
resolution and high mortality rates. The majority of the Staphylococci are commensal, 
however, they can be responsible for a variety of medical conditions caused by infection 
processes or the direct production of toxins (skin infections, deep tissue infections, toxic 
shock syndrome, septicemia, endocarditis). 
Treatment failure in Staphylococci has been associated with their ability to form biofilms, 
which have been implicated in chronic and recurring infections. Another physiological state 
that has been suggested to be of clinical importance is persister cells. Despite the lack of solid 
evidence on their clinical manifestation, persister cells have also been implicated in chronic 
infections. In Paper II, we aim to investigate the role of bacterial physiology in antibiotic 
refractoriness. We provided evidence of biofilm derivation for a significant fraction of 
persister cells. In Paper III, we investigated the effect of incubation atmosphere on the 
susceptibility of biofilm-derived cells and demonstrated an increased refractoriness of S. 
aureus biofilm-derived cells under anaerobic conditions. 
Polymicrobial communities play a major role in human health and disease. Recent studies 
have demonstrated that the gut microbiota modulates brain development and behavior. In 
Paper IV, we aim to investigate peptidoglycan sensing in the developing brain. In this study 
we provide solid evidence of a signaling pathway mediating the communication between the 
gut microbiota and the developing brain. 
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1 BACKGROUND 
1.1 ANTIMICROBIALS 
Antimicrobials are chemical substances that inhibit or kill microorganisms. They can be 
derived from other microorganisms or synthetically produced. Special emphasis in this thesis 
will be given to antibiotics. The term antibiotic is given to any drug that can be used to treat 
bacterial infections. Antibiotics are usually low molecular weight organic compounds, 
produced as secondary metabolites by microorganisms that selectively inhibit the growth of 
other microorganisms.  An overview of the different classes of antibiotics and their targets is 
summarized in Figure 1. Evolutionarily, the role of these molecules has been hypothesized to 
be to confer an ecological advantage for survival in natural environments where resources are 
limiting for bacterial growth. 
 
 
Figure 1. An overview of the different classes of antibiotics 
 
Long before the introduction of antibiotics, different civilizations in the course of history had 
utilized beer yeast, mold and mushrooms to treat infected wounds. In ancient Egypt and 
Greece, physicians used compresses and tonics made from herbs, molds and organic 
compounds to treat patients. Despite the fact that they were unable to explain the reason of 
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this effect, they harnessed the healing powers of natural compounds. Empirical treatments 
dominated medicine up until the discovery and description of bacteria.  
The discovery and subsequent mass production of antibiotics in the beginning of the 20th 
century was one of the most important achievements in modern medicine. The introduction of 
antibiotics, along with improvements in hygiene measures and a comprehensive 
understanding of pathogenic microorganisms, was instrumental for restricting many 
infectious diseases and had a profound positive effect on life quality and life expectancy. 
The first natural antibiotic to be described in modern history was discovered by a young 
medical scientist, Bartolomeo Gosio 1. He purified a substance from fungi growing on corn 
that exhibited activity against Bacillus anthracis (the causative agent of anthrax). This 
compound was some years later identified as mycophenolic acid. Ehrlich and Bertheim 
discovered the first synthetic antibiotic in 1909, which was an arsenic derivative called 
arsphenamine. Within less than a year from its discovery, arsphenamine (marketed as 
Salvarsan) was used for the clinical treatment of syphilis by 1910 2. 
Sulfonamides were the first class of antibiotics to be introduced in the clinic in the early 
1930s 3. Prontosil was marketed in 1935 and was very effective against gram-positive cocci 
(mainly Streptococcus) drastically reducing deaths from pneumonia, meningitis and childbed 
fever. However, it was the work of Sir Alexander Flemming that revolutionized antimicrobial 
treatment. Even though penicillin was first discovered (accidentally) in 1928, it was not until 
the early 1940s that it started being mass-produced and used in patient therapy. The discovery 
of beta-lactam (β-lactam) antibiotics is a hallmark in modern chemotherapy. The second half 
of the 20th century is dominated by the discovery of many new and important antibiotics, 
both natural and synthetic, with a wide range of activity. 
Antibiotics have long been indispensable for infection treatment but their indiscriminate use 
has driven the ascent and dissemination of antibiotic resistance. Many antibiotics are losing - 
or have already lost- their potency against major pathogens. This antibiotic resistance is 
brought about via five basic paths:  
• Modification of the antibiotic target molecule with mutation being the key factor.  
• Destruction of the antibiotic before entering the cell via cleavage by specialized 
enzymes.  
• Modification of the antibiotic molecule that leads to inactivation.  
• Active pumping of the antibiotic outside the cell with the use of specific or non- 
specific transport proteins.  
• Reduced uptake of the antibiotic by bacterial cells.  
 
Upon discovery, antibiotics were considered the “magic bullet” against all pathogenic 
microorganisms, leading to the US surgeon General in 1968 to declare that the battle against 
infections was won. It soon became clear that this notion was far from the truth. Bacteria 
utilize a very diverse arsenal while evading the host’s defense mechanisms in order to 
establish themselves in host organisms. Through drug evasion and/or degradation, primary 
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resistance, phenotypic resistance, sub-optimal growth and residence in protected 
environments (intracellularly or in biofilms), bacteria manage to persist during antibiotic 
exposure. 
A very good example showing the potential clinical relevance of these mechanisms is that of 
community-acquired pneumonia patients infected by susceptible strains of Streptococcus 
pneumoniae that are unresponsive to antibiotic therapy 4. As a consequence of the above-
stated mechanisms of survival in lieu of primary resistance, the question why antibiotic 
therapy fails arises. A valid answer is the evolution of resistance and the dissemination of 
resistance cassettes horizontally among non-related species. However, these two mechanisms 
cannot account for all clinical failure. Antibiotics can sometimes fail due to a non-inherited 
refractoriness that results from differential physiology. This physiology is in turn affected by 
population age, physical structure, antibiotic pre-exposure and quorum sensing amongst 
others.  
The rate of discovery for new antibiotics or antimicrobial agents has been in decline over the 
last three decades, and taken together with the spread of drug multiresistance, the need for 
alternative methods to combat infection is evident. Now, more than ever, is imperative to 
experimentally identify optimal regimens that will both conclude in successful patient 
treatment and also suppress the emergence of resistance. 
 
1.1.1 Antibiotics used in this study 
Ampicillin 
Ampicillin is a β-lactam antibiotic of the penicillin class with broad-spectrum activity and 
listed in the World Health Organization’s (WHO) “List of essential medicines” 5. It is an 
irreversible inhibitor of the enzyme transpeptidase, which is essential in bacterial cell wall 
biosynthesis. It has traditionally been used for the treatment of respiratory tract infections, 
urinary tract infections (UTIs), meningitis, and endocarditis. 
Ciprofloxacin 
Ciprofloxacin is a second-generation fluoroquinolone with broad-spectrum activity, also 
listed in the WHO’s “List of essential medicines” 5 . It inhibits the function of DNA gyrase, 
and a type II topoisomerase (topoisomerase IV), both necessary in bacterial DNA replication 
6. It has been used for the treatment of a wide range of conditions, such as skin and deep 
tissue infections, typhoid fever, respiratory tract infections, UTIs, and sexually transmitted 
diseases. 
Daptomycin 
Daptomycin is a lipopeptide antibiotic mostly used in infections caused by gram-positive 
bacteria. It has a distinct mechanism of action, inhibiting a number of different cell 
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membrane functions. More specifically it inserts into the cell membrane and aggregates. This 
aggregation alters the curvature of the membrane inducing the formation of holes that leak 
ions. The depolarization and resulting loss of membrane potential leads to rapid bacterial cell 
death 7. Daptomycin has been used to treat infections caused by multiple drug-resistant 
bacteria. Most commonly it has been used against Staphylococcus aureus (S. aureus) 
bacteraemia and endocarditis, and other gram-positive mediated skin infections. 
Gentamicin 
Gentamicin belongs to the aminoglycoside class and is listed in the WHO’s “List of essential 
medicines” 5. It is mostly active against gram-negative bacteria, but also the gram-positive 
Staphylococci. It irreversibly binds the 30S subunit of the bacterial ribosome, thus 
interrupting protein synthesis. It has a wide range of applications and has been used against 
pneumonia, meningitis, UTIs, endocarditis, sepsis and deep tissue infections.  
Linezolid  
Linezolid is a member of the oxazolidinone class and is also part of the WHO’s “List of 
essential medicines” 5. It is used for the treatment of infections caused by almost all clinically 
important gram-positive bacteria that are resistant to other antibiotics. It binds to the 23S 
rRNA of the 50S ribosomal subunit occupying the A site. There, it induces a conformational 
change that prevents tRNA from entering the site and forcing tRNA to fall off the ribosome, 
ultimately blocking initiation of translation 8. Linezolid is considered bacteriostatic against 
most organisms in vitro, however in vivo bactericidal action can be exhibited by inhibition of 
toxin production in Staphylococci and Streptococci. It is used in the treatment of skin 
infections, pneumonia and drug-resistant tuberculosis. 
Nalidixic acid 
Nalidixic acid is a first-generation fluoroquinolone mostly effective against gram-negative 
bacteria. It has the same mechanism of action as ciprofloxacin. Historically it had been used 
for the treatment of UTIs, however, now it has been replaced in the clinic with more effective 
and less toxic drugs. 
Oxacillin 
Oxacillin is a β-lactam antibiotic of the penicillin class with a narrow spectrum of activity. It 
inhibits the synthesis of the peptidoglycan layer of bacterial cell walls by binding to the active 
center of penicillin-binding proteins and preventing the final cross-linking of the growing 
peptidoglycan layer. It is penicillinase-resistant and consequently has been used widely to 
treat penicillin-resistant S. aureus related infections. 
Streptomycin 
Streptomycin is an aminoglycoside with broad spectrum activity and included in the WHO’s 
“List of essential medicines” 5. It binds to the 16S rRNA of the 30S subunit of the bacterial 
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ribosome, interfering with the binding of the formyl-methionyl-tRNA, which in turn induces 
frame-shift mutations and defective protein synthesis 9. It is used to treat endocarditis, 
tuberculosis (in combination with other antibiotics), brucellosis and plague, among other 
conditions. 
Tetracycline 
Tetracycline belongs to the tetracycline class of antibiotics and also listed in the WHO’s “List 
of essential medicines” 5. It has a broad range spectrum of activity and has been used for the 
treatment of a variety of conditions such as acne, cholera, brucellosis, plague, malaria and 
syphilis. It binds to the 30S subunit of bacterial ribosomes where it blocks the attachment of 
charged aminoacyl-tRNA to the A site, thus inhibiting protein synthesis in susceptible 
bacteria. 
Vancomycin 
Vancomycin is a type of glycopeptide antibiotic and indexed in the WHO’s “List of essential 
medicines” 5. It recognizes and binds to the two D-alanine residues on the end of the peptide 
chains preventing cross-linking of the growing peptidoglycan layer. It is considered a last 
resort medication for the treatment of septicemia and lower respiratory tract, skin, and bone 
infections caused by gram-positive bacteria. 
 
1.1.2 Antimicrobial susceptibility testing methods 
Antimicrobial susceptibility testing may be the single most important activity performed in 
the clinical microbiology laboratory 10. It is of paramount importance to reliably detect 
antibiotic resistance in microorganisms and ensure a successful antimicrobial treatment. A 
number of different methods have been developed and each of them has its own advantages 
and disadvantages, as well as to which microorganisms can be accurately used on. Some of 
the methods provide quantative results (minimum inhibitory concentration) while others offer 
qualitative results (susceptible, intermediate or resistant). Nevertheless, all of the methods are 
either based on confirming susceptibility or detecting resistance to antimicrobial agents. 
Dilution methods 
The broth dilution method is based on challenging a microorganism with a series of 
concentrations of antimicrobial agents in broth environment. There are two variations of this 
method depending on the broth volume; microdilution testing in volumes of 100 µl and 
macrodilution testing in volumes up to 1 ml. The latter was one of the first antimicrobial 
susceptibility methods to be developed 11. For both methods, a two-fold dilution of an 
antibiotic is prepared in a liquid growth medium. A standardized bacterial inoculum of 1–5 x 
105 colony forming units per ml (CFU/ml) is then added, allowed overnight incubation at 35 
oC and then turbidity is assessed 12. The lowest concentration of an antibiotic that visibly 
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inhibits the growth of the microorganism is recorded as the minimum inhibitory 
concentration (MIC).  
A similar technique has been developed for MIC assessment on agar plates called agar 
dilution method. This method follows the same principle to identify the lowest concentration 
of the serially diluted antibiotic at which bacterial growth is still inhibited. 
The major advantages of these techniques have been the quantitative output, presented by a 
defined MIC concentration, and reproducibility. The precision of this technique is plus or 
minus a dilution step. Among the major weaknesses of the dilution methods are the long time 
to prepare the experiment, possible pipetting errors and errors in preparation of the antibiotic 
solutions. 
Disk diffusion method 
The disk diffusion susceptibility method is very simple and has been well standardized 13. An 
inoculum of approximately 1-2 x 108 CFU/ml from the microorganism is evenly seeded on an 
agar plate. Commercially prepared disks, each of which is pre-impregnated with a standard 
concentration of a particular antibiotic, are then dispensed onto the agar surface. The 
antibiotic begins to diffuse outward from each disk, creating a gradient of antibiotic 
concentration in the agar. The plates are allowed to incubate for 16–24 h at 35 oC and the 
bacterial growth around the disks is monitored. If the microorganism is susceptible, a clear 
zone of inhibition will be observed around that disk. The diameter of the zone is measured in 
millimeters and then compared to an interpretation chart 12 allowing classification of the 
microorganism as susceptible, intermediately susceptible or resistant. No actual MIC value 
can be obtained with this test. 
This method is gaining popularity due to its convenience, efficiency and cost, and it is 
probably the most widely used method for determining antimicrobial resistance patterns in 
clinics. Most likely the major disadvantage of this method is the lack of automation. 
Moreover, according to the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) a number of organism-antimicrobial agent combinations do not provide reliable 
results 14. 
E-test 
E-test (AB Biodisk, Sweden) is a commercially available test that utilizes a plastic strip 
impregnated with a gradually decreasing concentration of an antibiotic on the bottom side, 
while the upper surface has a concentration scale. A suitable agar plate is inoculated with a 
standardized inoculum as in the disk diffusion method mentioned above. Up to six different 
strips can be arranged in a radial fashion on the agar surface. Plates are then incubated 
overnight and the MIC is determined by the intersection of the lower part of the ellipse 
shaped growth inhibition area with the test strip. 
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This method is a convenient quantitative test of antibiotic resistance that has been used to 
assess clinical isolates.  However, a separate strip is needed for each antibiotic, and therefore 
the cost of this method can be quite high. In general, results obtained with E-test have 
correlated well with MICs generated by broth or agar dilution methods 15. Conversely, certain 
organism-antimicrobial agent combinations are known to show systematic biases when 
assessed by E-tests 16. 
Automated antimicrobial susceptibility testing methods 
A number of different commercial systems have been developed to facilitate high throughput 
of antimicrobial testing 17. The actual assessment of antimicrobial susceptibility is based on 
broth microdilution method, with these automated systems providing inoculation, reading and 
interpretation. Despite the high sample throughput and convenience, such systems can be 
quite expensive to purchase and maintain in laboratory settings. Some examples of these 
include: Vitek 2 System (bioMerieux), Sensititre ARIS 2X (Trek Diagnostic Systems), 
MicroScan WalkAway (Siemens Healthcare Diagnostics) and Phoenix (BD Diagnostics). 
Mechanism-specific tests 
Such tests are based on directly detecting particular resistance mechanism(s). They are 
usually developed for antibiotics with a well-understood background on resistance 
acquisition.  Some examples are the chromogenic cephalosporinase test 18 used to detect the 
presence of β-lactamases and the chloramphenicol acetyltransferase (CAT) reagent kit 19 that 
detects the presence of this chloramphenicol-modifying enzyme.  
Genotyping methods 
When resistance to a given antibiotic is genetically encoded, there are methods to evaluate the 
presence of specific genes that confer antibiotic resistance. Two of the most common 
molecular techniques used in antimicrobial resistance detection are: Polymerase Chain 
Reaction (PCR) and DNA hybridization. 
PCR based methods are the most commonly employed. They are based on the direct 
amplification of known resistance genes and can provide highly reliable and rapid results. 
DNA hybridization techniques are based on direct identification of target sequences with 
specifically designed probes. When hybridization occurs, a signal (enzymatic, radioactive or 
luminescent) is produced; if the sequence in question is not present no signal will be detected. 
Both approaches offer high sensitivity and specificity in detection. 
Even though nucleic acid-based systems are rather fast and inexpensive, the presence of a 
resistance-related gene does not necessarily result in treatment failure because resistance is 
also dependent on the mode and level of expression of these genes. Moreover, these 
techniques have limited utility, since only a few resistance genes are firmly associated with 
phenotypic resistance. 
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1.2 BIOFILMS 
The concept of bacteria living in sessile communities, knowledge we now take for granted, 
has not been so widespread in the past. The first publication to acknowledge bacterial growth 
on surfaces comes from the works of the zoologist Claude Zobell in 1943 20. Within the forty 
following years there were sporadic reports investigating surface-associated bacterial growth 
and their role in natural environments and in pathology. It was only in 1987 when surface-
associated lifestyle was termed biofilm and was recognized as the major form of existence for 
many microorganisms 21. 
A biofilm is defined as “a structured community of bacterial cells enclosed in a self- 
produced polymeric matrix and adherent to an inert or living surface” 22. Biofilms are 
universal 23,24 and all surfaces that come in contact with a naturally occurring liquid are 
susceptible to this form of bacterial colonization. Mature biofilms are characterized by 
intricate three-dimensional structures that have channels and pores allowing exchange of 
material with the environment 24. Their architecture varies and can be influenced by a variety 
of factors (e.g. internal pH, carbon source, oxygen perfusion, location, nature of comprising 
bacteria and osmolarity, among others) 25,26.  
It is generally accepted that biofilms constitute a protected mode of life when environmental 
conditions are not favorable. It has also been suggested that biofilm-residing bacteria 
metabolically perform better than their planktonic counterparts 27. Biofilms function as gene 
pools and greatly facilitate exchange of genetic material mostly by horizontal gene transfer 28. 
The biofilm mode of life is very successful among bacteria, but also extends to other life 
domains like archea 29, fungi 30 and algae 31. In most natural environments biofilms are 
inhabited by a large number of different species, where the first colonizer usually conditions a 
surface and provides a holdfast for the attachment of other colonizers, and/or the metabolic 
by-products of one might serve as nutrients for the other 27,32. 
It is now evident that in medical, industrial and natural settings the formation of biofilm 
seems to be the most common mode of life. As a strategy it demonstrates a selective 
advantage, coupled with a higher probability of survival for those sessile bacteria 21,22. 
Biofilms exhibit a remarkable ability to resist a variety of biocides and this resistance can be 
up to 1000-fold higher than that of planktonic cultures in some cases 33. Moreover, biofilms 
have been associated with increased resistance against host defenses and immuno-evasion 34-
36. This tenacity of biofilms, combined with the high refractoriness of biofilm-associated 
infections, calls out for new approaches in combating such infections. 
 
1.2.1 BIOFILM MATRIX 
Biofilms have two major components: cells and the matrix enclosing them (Figure 2). The 
matrix holds the biofilm together and accounts for many of its functions 37. In addition to 
acting as a physical barrier protecting the cells, it facilitates cell-to-cell communication 
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through specialized biochemical signals 38. The matrix is composed of materials called 
extracellular polymeric substances (EPS), mainly comprised of complex polysaccharides, 
proteins, extracellular DNA (eDNA), amyloid fibers and lipids 37. The major components 
though, are carbohydrates and proteins 39. 
 
 
Figure 2. Scanning electron micrographies showing biofilm formation. After the initial attachment on 
a surface (white arrow in A) the bacteria start producing EPS components (black arrow in A) and 
eventually they are encased by the biofilm matrix (B) (Modified from 40). 
 
Matrix composition has a great impact on a biofilms’ physicochemical properties and 
subsequently on its survival. It affects nutrient adsorption, mechanical stability, density, 
porosity and hydrophobicity, among others that are vital for biofilm survival 41. It protects the 
enclosed cells from environmental stress factors (e.g. dehydration, predation, oxidation 
stress) and treatment from antimicrobial agents. Despite the fact that the exact content of the 
matrix differs from one biofilm to another, there is speculation of some characteristics being 
shared by all of them 37. 
Microbial activity in biofilms is defined by the composition, structure and properties of the 
polymers that comprise the matrix 42. These polymers have effects on oxygen diffusion, 
substrate absorption and transport of molecules throughout the matrix. The chemical 
composition and physical properties of the polysaccharides vary significantly among biofilm 
matrices. The differences can be on the type of monomers that constitute the polysaccharides, 
the type of glycosidic linkages (β-1,4, β-1,3 or α-1,6) and the frequency of different organic 
and inorganic substitutions. Characterization of EPS components is essential in understanding 
the structure-function relationship in biofilms.  
Another important function of the matrix is to facilitate cell-to-cell communication. Within 
the biofilm structure -where high bacterial densities are achieved- small molecules are 
excreted facilitating communication and thus allowing the bacteria to modify their behavior 
in a coordinated manner 38. This process has been called quorum sensing and it is strongly 
related to virulence and biofilm dispersal mechanisms. Moreover, such close proximity of 
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cells allows for greater chances of successful genetic material exchange when compared to 
planktonic cultures 43. Lastly, the matrix acts as a barrier retaining a pool of extracellular 
enzymes in the cells’ vicinity and limits diffusion of nutrients from lysed cells. 
 
1.2.2 BIOFILM DEVELOPMENT 
Biofilm formation is a complex process that involves a coordinated gene expression and a 
tight regulation of a big set of diverse genes. The development of a biofilm can be 
summarized in 5 steps: i) reversible attachment, ii) irreversible attachment, iii) maturation I, 
iv) maturation II and v) dispersal 44 (Figure 3). 
 
 
Figure 3. The five developmental stages of biofilm formation. I) reversible attachment, II) 
irreversible attachment, III) maturation I, IV) maturation II and  V) dispersal  
 
Reversible attachment 
The first step in establishing a biofilm is the close proximity of a bacterium and a surface. 
Bacteria can reach a surface actively by chemotaxis and motility or by chance through liquid 
flow. Whether attachment is favored or not depends on the net repulsive forces (electrostatic 
interaction, Van der Waals, hydrodynamic forces, hydrophobic interaction) occurring when 
the distance between cell and surface is approximately 1 nm. Different approaches are 
employed by bacteria to attach to different materials/surfaces. In general, attachment to 
abiotic surfaces is mainly non-specific, while attachment to biotic surfaces utilizes specialized 
molecular docking appendices (e.g. pili, adhesins, fimbriae) 45. 
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Irreversible attachment 
This initial step is a dynamic process and cells can detach from the surface since attachment 
is reversible. Once attachment is favored, it becomes non-reversible with the production of 
EPS material and/or the induced expression of adhesive proteins. By the end of this phase, 
bacterial cells are steadily fixed on the surface. 
Maturation I 
The next phase involves additional production of adhesion molecules and cell division. 
Biofilm matrix is being produced and the attached cells give rise to microcolonies. This phase 
concludes with the early architectural characteristics of the biofilm being present. 
Maturation II 
During this phase biofilm complexity achieves its maximum capacity. The bacteria reach a 
maximum density and continuously produce extracellular polymeric substances giving rise to 
intricate three-dimensional structures. The mature biofilm extends towards its environment 
and is dominated by channels and pores that allow liquid flow through the structure 24. 
Biofilm architecture is not consistent, and factors such as internal pH, availability of carbon 
sources, oxygen perfusion, location, nature of comprising bacteria and osmolarity have been 
shown to affect it 25,26. 
Dispersal 
The last stage in the biofilm mode of life is dispersal, when bacteria leave the biofilm and 
return to a planktonic lifestyle. It can occur in two ways: naturally or by external forces 46. 
The natural dispersal is a highly regulated process that depending on the environmental 
conditions allows for extended colonization of a favorable niche or triggers the bacteria to 
search for new locations 47. On the other hand, biofilm colonization can occur by external 
forces such as physical detachment or shear forces. 
 
1.2.3 SIGNIFICANCE OF BIOFILMS 
Biofilm related infections account for approximately 65% of the hospital-acquired infections 
48. Their ability to form on a variety of surfaces, and more specifically within indwelling 
medical devices (e.g. catheters, prosthetic devices), draws attention to their vast clinical 
impact. There is compelling evidence that biofilms contribute to chronic as well as latent 
infections 49,50. They have been also correlated with high risk of medical implant rejection 
with associated severe complications 51. Oral biofilms, on the other hand, have been linked 
with a variety of pathological conditions 52. 
Biofilms do not only have clinical implications but are also involved in health risks in daily 
life.  Examples of this are found in the food and beverage industry. Biofilms forming on food 
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products are generally hard to eradicate, thus compromising food quality 53. Moreover, 
biofilm emerging inside water pipes can have a negative effect on water quality. 
In industrial settings biofilms can lead to great financial damage. A well documented 
example is the oil industry, where biofilm forming in distribution pipes can lead to corrosion, 
blockages or even spoil the oil or gas 54. Another common issue is biofouling, where biofilm-
related communities cause corrosive damage or potential blockages.  
Despite their negative impact in clinical and industrial settings, biofilm formation can be 
harnessed for beneficial purposes. Biofilm communities have been used as molecular filters 
in sewage treatment and for bioremediation in contaminated marine systems 55. 
 
1.3 PERSISTERS 
Shortly after the introduction of penicillin, a physician named Joseph Bigger observed that 
increasing concentrations of penicillin added to a culture of S. aureus induced lysis, but the 
lysed material gave rise to fresh colonies upon plating. Bigger concluded that penicillin was 
not able to sterilize an infection and named the surviving cells “persisters” 56. It has been 70 
years since the observation of persister cells and we still do not have a complete answer 
regarding the mechanism of their formation.  
“Bacterial persister cells are dormant variants of regular cells that form stochastically in 
microbial populations and are highly tolerant to antibiotics” 57. Persistence is to be 
differentiated from antibiotic resistance since persister cells do not differ genetically from 
their susceptible counterparts in a population. Indeed, cultures grown from persisters are as 
sensitive to the drug as the parental culture the persisters originated from 58. It is generally 
accepted that persistence arises from phenotypic population heterogeneity within an isogenic 
population. Balaban et al. have proposed that there are two types of persister cells: type I cells 
that exhibit a reduced exit rate from stationary phase, as opposed to type II cells that 
constantly interconvert between the persister and susceptible state 59.  
The tolerance of persister cells has mainly been associated with entry to a non-growing 
physiological state where the cell metabolism is kept to the minimal essential required for 
survival. The physiology of persisters is often compared with that of stationary phase cells. 
Indeed, stationary phase cultures have been extensively used as a model of non-growing 
population and most of the understanding we have about persisters comes from challenging 
these cultures with different antibiotics 60,61 
Experimental study of persisters is challenging due to a number of complications. Most 
notably, current data suggest that the persister population is not stable with a constant 
interconversion between the persister and susceptible state 59,62. The number of persisters is 
really small in a given culture, with only 1 in 105-106 cells in a wild type Escherichia coli 
(E.coli) culture 63. Moreover, when identical cultures are exposed to different antibiotics there 
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is substantial difference in persister levels 61,64. In order to begin understanding what 
persisters are, one must keep in mind that they are a heterogeneous population with 
physiological diversity arising from cell to cell variability in any number of cellular processes 
(Figure 4).  
 
 
Figure 4. Persister cell formation can be stimulated by environmental and physiological cues. 
 
The first evidence of a genetic link to persister formation has been the discovery of the hipA7 
gain of function allele 58. However, a deletion of the hipA gene showed no relative phenotype. 
In recent years, the increased availability of different knockout and transposon mutant 
libraries has led to a more straightforward approach based on screening towards the 
molecular characterization of persistence mechanism. A screening of the E. coli gene 
knockout KEIO collection 65 failed to identify any gene that eliminated persister formation 60. 
In the same study, only a number of global regulators knockouts showed a 10-fold decrease 
in persister formation, suggesting a higher degree of redundancy in whatever mechanism(s) 
might be involved in persister formation. Screening studies in other species produced similar 
results 66. 
A number of genetic studies have linked persistence to toxin-antitoxin systems 67, stringent 
response 68, levels of DNA damage 69 and more recently changes in metabolic pathways 70. 
These observations strengthen the argument of redundant pathways and functional overlap in 
persister formation. It is evident that the cellular metabolic state seems to be an important cue 
driving persister formation. Moreover, the role of DNA damage repair systems 69 adds 
towards the argument that persister formation might be inducible 59.  
Bacterial persistence has often been perceived as a model of survival in fluctuating 
environments. As elegantly stated by Kusell et al., “persisters are an insurance policy against 
antibiotic encounters” 71. It is an epigenetic strategy to reduce the risk associated with fast 
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growth in nutrient rich environments. A fraction of the population is characterized by 
suppressed growth when the remaining population grows exponentially. The lowering of the 
population fitness is in fact a risk-reducing solution that improves the odds of survival of a 
population under any type of stress (antimicrobials, host defenses or environmental factors).  
Some promising studies have revealed enhanced clearance of persisters from infection 
models or reduced persister formation in in vitro systems. Li & Zhang found that inactivation 
of phoU resulted in enhanced bacterial death for many antibiotics and environmental stresses 
61. Notably, a study from Allison et al. established a strategy to remove persisters in a mouse 
UTI model through aminoglycoside potentiation by specific metabolic stimuli 72. More 
recently, Lebeaux et al. demonstrated the ability of pH-mediated potentiation of 
aminoglycosides to eradicate persisters in catheter-related infections 73. 
Persister cells have been suggested to play a major role in recurring chronic infections 74,75. 
High persister mutants have been isolated from a number of infections regardless of site of 
infection and species, such as Pseudomonas aeruginosa from cystic fibrosis patients 76 or 
Candida albicans from oral thrush biofilm 77. Furthermore, they have been implicated in 
tolerance not only to antibiotics but also to other toxic molecules such as heavy metals 78. The 
failure of most antibiotics to control persister populations only highlights the importance of 
understanding the molecular mechanism(s) governing persister formation. 
 
1.4 SMALL COLONY VARIANTS (SCV) 
Small colony variants were first described in 1935 for S. aureus 79 and soon after in various 
coagulase-negative Staphylococci. At first they were believed to be part of the normal 
bacterial cell cycle, but it took almost 80 years to show that phenotypic switching between 
normal and SCV phenotypes occurs during exponential growth even in the absence of any 
selective pressure 80. The SCV phenotype is linked to chronic, recurrent, and antibiotic-
resistant infections 81. Occurrence of SCVs is not limited to human clinical infections, but is 
also found in veterinary infections 82 and in the food industry 83. 
The molecular mechanism behind SCV emergence has not yet been fully elucidated. Until 
now six different pathways/mechanisms have been well described: menadione-dependent 84, 
hemin-dependent 85, thymidine-dependent 86, fusidic acid-resistant 87, with an impaired stress 
response 88 and with impaired stress response to cold shock 89. Ongoing research supports the 
notion that some SCVs might rise as an effect of yet unrecognized regulatory genes, due to 
the fact that a portion of them return to normal phenotype upon subculture 90. 
SCVs have been associated with invasion of mammalian cells and intracellular persistence 
91,92. Genetic and expression studies of SCVs have provided numerous clues to support the 
above notion. S. aureus SCVs have been described with high expression of adhesins and 
production of fewer lytic enzymes that facilitate persistence and host cell uptake 91. 
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Moreover, SCV phenotypes are highly associated with down-regulation of the tricarboxylic 
acid cycle and other metabolic pathways 93. 
Along with the formation of biofilm and persister cells, SCVs have been suggested to be a bet 
hedging strategy under stress conditions in the form of a phenotypic switch 94. It is generally 
accepted that the emergence of SCVs is enhanced in strains with mutator phenotypes, which 
are affected in their DNA repair systems 85. SCVs are then selected either by environmental 
stress conditions 83 or by intracellular location 95. Due to the inherent difficulties in 
successfully treating infections associated with SCVs, more studies to optimize antibiotic 
therapy are needed. 
 
1.5 STAPHYLOCCOCUS AUREUS 
1.5.1 INTRODUCTION 
Staphylococcus aureus is a gram-positive coccus classified in the Firmicutes phylum. It is a 
facultative anaerobe that grows in clusters, often in hexagonal arrangement. Studies have 
shown that 1 out of 3 people are asymptomatic carriers, with the bacterium being part of their 
normal microbiota. It mostly resides on the skin, the respiratory tract and the perineum 96,97.  
The genome has approximately 2.8 million base pairs and may include one or more plasmids. 
Currently, there are 162 complete genome sequences available for S. aureus strains in the 
National Center for Biotechnology Information (NCBI) genome database and almost 8000 
genome assemblies have already been deposited 98. The general consensus is that 
approximately 75% of the genome is conserved among sequenced strains, but with each new 
strain being sequenced it is evident that the variable element is only growing. 
Although S. aureus is not always pathogenic, it is a common cause of a variety of conditions 
with diverse severity. Staphylococcal infections include minor skin infections, boils, wound 
infections, toxic shock syndrome, pneumonia, osteomyelitis, endocarditis, bacteraemia and 
sepsis, among others (see 99 for a more comprehensive review). The primary site of infection 
is the skin or superficial wounds 100, from where the organism can gain access to the 
bloodstream and invade host tissues with a variety of clinical manifestations. It is estimated 
that approximately half a million patients are hospitalized due to staphylococcal related 
infections in the USA alone 101. 
People with underlying chronic conditions such as diabetes, cancer, vascular disease, eczema, 
and lung disease are at higher risk of developing staphylococcal infections. Moreover, 
hospitalized patients are also at high risk, especially when immuno-compromised. S. aureus 
is the most commonly isolated bacterium in chronic wounds (93.5 %) followed by 
Enterococcus faecalis (71.1 %), Pseudomonas aeruginosa (52.2 %) and coagulase-negative 
Staphylococci (45.7 %) 102. Equally important, S. aureus and S. epidermidis are responsible 
for the majority of biofilm-mediated device-related infections in healthcare settings 103.  
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S. aureus is a highly adaptable microorganism with a broad niche and host range, that has 
often been associated with chronic and/or persistent infections 22,49. In general, staphylococcal 
virulence has been linked with the ability of the organism to grow in biofilms 104. However, 
biofilm formation in S. aureus will be discussed in more detail in the following section. 
Another disconcerting observation is the high rate of resistance acquisition to last resort 
antibiotics, such as vancomycin 105. The rise of multi-resistant strains is an ongoing problem 
for healthcare settings resulting in increased morbidity and mortality worldwide. The 
adeptness of S. aureus to survive and adapt to a spectrum of different environments only 
stresses the complications involved in its eradication. 
The rise of MRSA coincides with the conclusion of one year from the clinical introduction of 
methicillin for the treatment of staphylococcal infections 106. Since then, MRSA has been 
disseminated gradually and by the 1970s it emerged as a common cause of hospital acquired 
infection (HA-MRSA) 107. The first report of community acquired MRSA (CA-MRSA) 
comes in 1981 108 and up until the mid 1990s there was an increasing number of outbreaks 
109,110. What was striking was that the patients involved had not been previously exposed to 
healthcare settings. CA-MRSA is in most cases a skin infection, however, HA-MRSA can 
cause life threatening bloodstream infections, pneumonia and surgical site related infections 
101. 
Centers for Disease Control and Prevention (CDC) statistics show that 2% of the general 
population are carriers of MRSA 101. MRSA has been identified as a leading cause of 
infectious disease in humans and animals 111. The genetic basis of methicillin resistance has 
been traced to the staphylococcal cassette chromosome (SCCmec) encoding an alternative 
penicillin-binding protein 2a, which alters the binding efficiency of β-lactam antibiotics on 
the staphylococcal cell wall 112. Consequently, cell wall biosynthesis in MRSA strains is not 
affected even in the presence of otherwise inhibitory levels of β-lactam antibiotics. The first 
gene to be identified has been mecA and has most probably been acquired through horizontal 
transfer 113, while later on mecC 114 was described. 
 
1.5.2 STAPHYLOCCOCAL BIOFILMS 
1.5.2.1 GENERAL 
S. aureus is a clinically relevant pathogen implicated in a wide range of conditions. Due to 
the increased occurrence of antimicrobial resistance and its ability to evade the host’s 
immune system, treatment is limited and often ineffective.  Treatment failure has been 
strongly associated with the organism’s ability to form biofilms, which have been implicated 
in recurring and chronic infections 22. Biofilm-related infections account for approximately 
65% of the hospital-acquired infections 101. Even more important clinically, the majority of 
biofilm-mediated device-related infections are predominantly caused by either S. epidermidis 
or S. aureus 103. 
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The biofilm, as discussed earlier, has two major components: the cells and their embedding 
matrix. S. aureus can produce multi-layered biofilm structures with the matrix being of 
variable nature.  Earlier studies (naming the matrix glycocalyx or slime) delineated that it was 
composed mainly of teichoic acids (~80 %) and a mix of staphylococcal and host proteins 115. 
However, further analysis identified a specific polysaccharide antigen named polysaccharide 
intracellular adhesin (PIA) 116, also known as poly-N-acetyl-glucosamine (PNAG). There are 
two distinct methods for biofilm formation in S. aureus: PIA-dependent and PIA-independent 
117.  
PIA is a positively charged molecule that facilitates intercellular attachment of the negatively 
charged bacterial cell walls 118. The icaABDC locus is responsible for synthesis (icaA and 
icaD), translocation (icaC) and modification (icaB) of PIA. This locus is present in many 
staphylococcal species 119 and is associated with enhanced biofilm formation 120. Regulation 
of the locus is complex among staphylococci, but it is generally accepted that is regulated by 
stress conditions (lack of oxygen, extreme temperatures, osmolarity and exposure to 
antibiotics among others) 121. Regulatory gene icaR, located directly upstream from the ica 
locus, is a well documented negative regulator 122. Other genes that directly or indirectly have 
a demonstrated effect on PIA production are: sarA 123, srrAB 124, tcaR 125, rbf 126 and spX 127. 
Table 1 contains a summary of environmental factors that influence PIA expression. 
 
Table 1. Factors that affect PIA expression. 
Factor Reference 
Glucose 128 
Glucosamine, N-acetylglucosamine 129 
Quinupristin-dalfopristin, tetracycline 130 
Urea 131 
Anaerobiosis 132 
Iron limitation 133 
High osmolarity, high temperature 134 
Ethanol 135 
 
Despite the well-documented importance of the ica locus in biofilm formation, 
staphylococcal biofilms can also form in an PIA-independent fashion. A study investigating 
the role of arlRS (a two-component system known to repress biofilm formation) came to the 
conclusion that deletion of the above locus resulted in enhanced PIA production 136. 
However, when a double mutant was constructed with a deletion of the ica locus, biofilm 
formation was unaffected 136. Subsequent reports showed that strains with mutation in the ica 
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locus showed no deficiency in biofilm development 137 nor virulence 138. Fitzpatrick et al. 139 , 
working with four clinical MRSA strains, came to the conclusion that there is little 
correlation between ica locus expression and biofilm formation in S. aureus. All of the above 
studies suggested a PIA-independent method for biofilm development that was proposed to 
be strain-specific. 
In S. epiderimidis, PIA-independent biofilm formation was mediated by accumulation- 
associated protein (Aap) 140, while in S. aureus biofilm-associated protein (Bap) and Βap-
related proteins had the same effect 141. Both Aap and Bap are located on the cell surface and 
are involved in cell-to-cell aggregation. These observations pointed towards a proteinaceous 
cell-to-cell adhesion method for biofilm development that is PIA-independent. Some notable 
surface proteins with involvement in this mode of biofilm formation are: SasG, SasC, protein 
A, fibronectin-binding proteins (FnBPA and FnBPB), autolysins (AtlA and AtlE), wall 
teichoic acids, lipoteichoic acids, cell wall-anchored proteins (such as clumping factors A and 
B) and the fibrinogen-binding preotein SdrG/Fbe 118. 
 
1.5.2.2 BIOFILM FORMATION 
Biofilm formation, as described before, occurs in 5 phases: adhesion, attachment, maturation 
I, maturation II and dispersal. In this section the specific factors and events in biofilm 
formation of Staphylococci will be discussed. 
Adhesion/Attachment 
The initial attachment to an abiotic surface is highly dependent on two factors: the physico-
chemical properties of the material and the surface components of the Staphylococci 117. 
Surface components involved (but not limited) to the initial phases of attachment are wall 
teichoic acids 142, lipoteichoic acids 142, accumulation-associated protein (Aap) 143 and 
autolysins (AtlA 144 and AtlE 145). 
On the other hand, cell wall-anchored proteins are mainly responsible for adherence to biotic 
surfaces (such as host cells or plasma-coated prosthetic devices). Both S. aureus and S. 
epidermidis encode for a variety of microbial surface components that recognize adhesive 
matrix molecules, allowing adherence to extracellular matrix components, fibrinogen, 
fibronectin and plasma clots 146. Among the most important proteins involved in this type of 
attachment are: surface protein G (SasG) 147, Bap 148, FnbA and FnbB 149, clumping factors 
(ClfA and ClfB) 150 and fibrinogen-binding protein SdrG/Fbe 118. Moreover, a collagen 
binding protein (Can) has been identified in mediating adherence of S. aureus to cartilage and 
collagenous-rich tissues 151. 
Some of the above mentioned factors seem to have functions in attachment to both biotic and 
abiotic surfaces. Notably, autolysins have been shown to facilitate attachment to plastic 
surfaces 152 and also have binding sites for a variety of host matrix proteins 153. 
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Maturation & accumulation 
After the initial attachment, the cells start producing extracellular polysaccharides, eDNA and 
other matrix components. The nature of the matrix is dependent on both genetic and 
environmental factors 37. Intercellular aggregation is facilitated by PIA production (in the 
presence of a functional ica locus; ica-dependent) and/or by cell wall-anchored proteins (in 
the absence of ica locus; ica-independent). In both cases, the result is the complete 
encapsulation of the bacterial cells by the matrix, expansion of the cell number in the 
structure and finally the formation of a multi-layered biofilm. 
Dispersal 
The last stage in the biofilm mode of life is dispersal, where cells return to a planktonic 
lifestyle. Dispersal can occur under tight genetic control with the programmed expression of 
proteases, nucleases and phenol-soluble modulins, that enzymatically degrade matrix 
components or adhesion molecules 104. Moreover, quorum sensing molecules have been 
implicated in mobilizing biofilm cells. Environmental factors include shear stress, corrosion 
or chemical/mechanical intervention. 
 
1.5.2.3 BIOFILM REGULATION 
Accessory gene regulator (agr) and staphylococcal accessory regulator A (sarA) are among 
the best-studied global regulatory systems in S. aureus. It is generally accepted that they 
operate in opposing manners, with sarA being essential for attachment while agr system is 
mostly involved in dispersal mechanisms. The agr system is involved in the downregulation 
of genes encoding for cell wall-associated adherence factors 154, thus resulting in reduced 
initial adherence. Repression of agr is essential for biofilm formation while induction through 
auto-inducing peptides is critical for dispersal of mature biofilms 155. Moreover, agr is 
involved in the regulation of phenol-soluble modulins and nucleases, both implicated in 
biofilm dispersal mechanisms 156,157. On the other hand, sarA transcripts are shown to be 
upregulated in biofilm cultures when compared to planktonic cells 123. Strains with mutations 
in sarA exhibit reduced biofilm capacity 158. Furthermore, it has been suggested that sarA 
could protect the integrity of the biofilm matrix by inhibiting nuclease and protease 
expression 159. 
The rpoF operon in S. aureus encodes for the alternative sigma factor B (σΒ) 160. The role of 
σΒ in the regulation of biofilm formation is controversial. It was reported that icaR binds to 
the same region of the ica locus promote as σΒ, thus actively downregulating ica expression 
161. However, Valle et al. 123 showed that in a σΒ deletion mutant biofilm formation was not 
affected. Others reported that σΒ deficient strains could not produce biofilm 134,162. σΒ is 
known to upregulate genes involved in the early stages of biofilm formation (e.g. clumping 
factors and fibronectin-binding proteins) 163,164 while downregulating a wide range of 
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proteases involved in dispersal mechanisms 165. These conflicting reports suggest that the 
regulatory role of σΒ in biofilm formation may have a strain-specific effect. 
Two component systems that are involved in different processes of biofilm formation in 
Staphylococci are arlRS and lytSR. Interestingly, the regulatory role of arlRS is achieved 
differently in Staphylococci; in S. epidermidis it regulates biofilm formation in a PIA-
dependent manner 166, while in S. aureus it does so in a PIA-independent manner 167. The 
lytSR system directly acts on the lrg/cid operon which regulates cell lysis during biofilm 
formation 168. Both systems are known to participate in the events of bacterial autolysis and 
the release of eDNA, an important component of the biofilm matrix.  
 
1.5.2.4 BIOFILM TREATMENT  
Staphylococci are involved in a wide range of infections with biofilm contributing 
significantly to problematic treatment. Anti-biofilm therapeutics have developed to help treat 
these biofilm-mediated infections. There have been three different approaches towards an 
anti-biofilm treatment: development of vaccines, utilization of agents that interfere with 
essential biofilm factors and development of biomaterials with surfaces that hinder biofilm 
formation. 
There have been several experimental vaccines that showed promising results in animal 
infection models but it remains to be proven whether they have the desired clinical effect in 
humans. Two of the most prominent examples were by Kelly-Quintos et al. 169, that managed 
to raise antisera against PIA, and Rennermalm et al. 170 who targeted several surface proteins, 
such as the fibronectin-binding protein. More recently, a conjugate vaccine that contains 
antisera against PIA and clumping factor A led to accelerated immune response 171. However, 
it remains controversial whether vaccination will be an effective measure to control 
staphylococcal biofilm-mediated infections. 
Staphylococcal biofilm formation is multifactorial 104, which makes it challenging (if not 
impossible) to identify the single factor that is involved in biofilm formation in every 
staphylococcal infection. However, there have been efforts to target the biosynthesis of 
factors that seem to be involved in the majority of biofilm-mediated infections. In that case, 
PIA has been a well-researched candidate. Dispersin B, isolated from Actinobacillus 
actinomycetemcomitans, has the ability to degrade PIA and destroy staphylococcal biofilms 
172. Another anti-biofilm drug -although not biofilm specific- is the peptidoglycan degrading 
enzyme lysostaphin that is being evaluated for its therapeutic value against biofilms of S. 
aureus and S.epidermidis 173. 
The development of biomaterials with surfaces that decrease bacterial adhesion has been a 
very exciting approach on its own right. However, the genetic versatility of Staphylococci 
results in attachment to the majority of the polymers currently in clinical use. There have 
been efforts to coat biopolymers with antibiotics or other substances with antibacterial 
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activity but there was limited success. One of the major problems with such an approach has 
been the widespread plasmid-borne antibiotic resistance in Staphylococci. 
 
1.6 GUT MICROBIOTA & ITS IMPACT ON HUMAN HEALTH 
In recent years, the study of gut microbiota has attracted great research interest. At first, most 
studies focused on how it affects the regulation of digestive function and satiety 174, while 
more recently its role in other aspects of physiology is being investigated. There is growing 
evidence that variations in its composition have an impact on normal physiology and could 
contribute to diseases ranging from inflammation to metabolic conditions. The existence of 
an interlinked relationship between host and microbiota is now well accepted 175. 
The composition and thus the activity of the gut microbiota is dynamic through the 
development of the host and has been associated with host genome 176-178, nutrition 179,180 and 
lifestyle 181,182. Humans share almost a third of their gut microbiota, while the other two thirds 
show high levels of individuality 183. Regardless of the high levels of variations among 
individuals, it is generally regarded that community stability and species diversity are the key 
characteristics of a healthy microbiota. 
During the initial days of life the gut microbiota is subject to great fluctuation and 
characterized by low diversity 184. By the third year of life, its composition stabilizes and in 
general terms it remains relatively stable to an adult-like profile 185. The adult microbiota 
consists of more than 1000 species, more than 7000 strains and is mostly dominated by 
strictly anaerobic bacteria 183. Apart from bacteria, the gut microbiota also includes viruses, 
eukaryotic microorganisms and archaea, but their role in human health is less studied. 
The number of microorganisms inhabiting the gut is estimated in between the order of 1013 to 
1014, a number ten times higher than the number of cells in the human body 183. The 
collective number of genes carried by our microbiota exceeds by at least 150 times the 
number of human genes 183,186 and this has lead to the gut microbiota to be called as “the 
forgotten organ” 187.  More recent studies have suggested that the growing embryo in the 
womb might be already exposed to maternal microbes 188, raising questions on the impact of 
the mother’s microbiota on the development and maturation of the intestinal community. 
Despite the concept of community stability, there is constant reshaping of the microbial 
composition driven by complicated dynamic events influenced by diet, life-style choices, 
disease and antibiotic use. The first three factors have been shown to alter community 
composition very rapidly 181,182,189, while an antibiotic-related perturbation has a much slower 
response time, and restoration to a stable community may take weeks or even years to be 
achieved 190. More recently, urbanicity was associated with changes in microbial diversity 
and a profound effect on the gut microbiome functionality 191. 
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An important -but sometimes overlooked- fact is that there is considerable interpersonal 
variance in the gut microbiota composition of healthy individuals 192. Such observation 
comes with the realization that there are multiple possible combinations that could constitute 
a healthy gut microbiota, while at the same time stable communities could also be associated 
with certain disorders 193. Should we consider the redundancy and pleiotropy of specific 
microbial members in the overall community composition, it would be rational to think that 
the functional output of multiple possible combinations could be in theory equivalent or 
similar. 
It has been suggested that the gut-brain axis is a bi-directional route of communication based 
on neural, hormonal and immunological signals. This communication is considered critical in 
order for the host to maintain essential functions. The gut microbiota has a profound 
influence on different aspects of human physiology not only limited to the gut-brain 
communication axis. It has been associated with pathological conditions that range from 
inflammatory diseases and obesity to irregularities in behavior and/or physiology that are 
associated with neurodevelopmental disorders. 
The gut microbiota is known to play an important role in the development and functionality 
of innate and adaptive immune responses 194,195 and in the regulation of gut motility, intestinal 
barrier homeostasis, nutrient absorption and fat distribution 196,197. Changes in the gut 
microbiota have been linked with neurological and psychiatric disorders 198 and more 
importantly have been shown to modulate brain development and behavior 199. On the other 
hand, there are studies demonstrating that stress in adulthood modifies the composition of the 
gut microbiota 200. Moreover, other conditions that have been associated with alterations in 
the gut microbiota are atopic dermatitis 201, systemic lupus erythematosus 202, inflammatory 
bowel diseases 203,204, type 1 diabetes 205 and multiple sclerosis 206.  
The major question that seems to be dominating the field is: does a disease lead to an altered 
microbiota, or does an altered microbiota directly contribute to the disease? In order to 
provide a comprehensive answer, prospective and intervention studies are required. Despite 
rigorous scientific investigations, often more questions arise than answers. For example, a 
recent study showed that bacterial infection promotes amyloid-β peptide aggregation, 
suggesting that neurodegeneration in Alzheimer’s disease could be linked to host responses to 
microbial infections 207.  
The discovery of the profound effect of the gut microbiota on human health (and disease) has 
led to the formation of large collaborative projects (MetaHit, Human Microbiome Project, 
MyNewGut) that have taken metagenomic-based approaches in investigating the cross talk 
between the gut microbiota and the host. These projects have greatly contributed to our 
understanding of the importance of the gut microbiota. Furthermore, they have contributed to 
the association of specific microbial communities with different human diseases, to define 
environmental factors affecting community dynamics and to the creation of genetic 
catalogues of reference microbial genes 183,208-210. 
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Consequently, the modulation of the gut-brain axis -by altering the gut microbiota- has been 
suggested as a possible process for the development of novel treatments. Three therapeutic 
approaches have been suggested for gut microbiota treatments: probiotics, antibiotics and 
fecal microbiota transplantation (FMT). Probiotics are defined as “live microorganisms that, 
when administered in adequate amounts, confer a health benefit on the host” 211. A number of 
studies have proposed the potential of probiotics in the treatment and prevention of diseases. 
The most commonly employed microorganisms are lactic-producing bacteria such as 
Lactobacillus and Bifidobacterium. Despite the fact that their exact mechanism of conferring 
benefits is not elucidated yet, it has been suggested that they qualitatively change the 
microbiota composition. Antibiotic treatments alter significantly the composition of the gut 
microbiota by disrupting its steady state and providing niche for expansion of existing 
bacteria or establishment of newly introduced ones. FMT has shown promising clinical 
results in the treatment of recurrent Clostridium difficile infections 212 and has been reported 
to have a beneficial effect in metabolic syndrome 213. 
The greatest challenge in the field has been the translation of the vast metagenomic data into 
a mechanism of biological relevance. The inability of in vitro culturing the complete human 
microbiota hinders efforts to comprehend the complex microbial interactions and the 
ecological implications of such communities. A possible solution to this has been the effort to 
identify major metabolites of microbial origin that could modulate physiological processes. 
This approach would greatly improve our mechanistic understanding of how the microbiota 
and the host are fine-tuned. Another subject of interest has been the mapping of antibiotic use 
early in life and the impact it has in shaping the microbiota and its relative functions. The 
ability to manipulate the microbiota in early life, when its composition is still dynamic, could 
potentially confer great health benefits later in life. 
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2 AIMS OF THE THESIS 
Understanding the interplay among the host’s innate defenses, the virulence arsenal of the 
pathogen and antibiotic treatment strategies will provide mechanistic insights on antibiotic 
pharmacodynamics, bacterial pathogenesis and will be invaluable for the development of 
novel therapeutic interventions.  
The overall focus of this thesis has been the study of antibiotic pharmacodynamics. Most of 
my research has been on biofilms and persister cells with a clear focus on S. aureus. My main 
aim has been to assess whether bacterial physiology has an effect on antibiotic refractoriness. 
 
My specific aims were: 
I. The development and validation of a mathematical model based on chemical 
reaction kinetics that can explain complex patterns of antibiotic action. 
II.  To study the consequences of long-term culture on antibiotic susceptibility of S. 
aureus using a pharmacodynamics approach, while evaluating a possible link 
between biofilm formation and persister cells. 
III. The in vitro characterization of the antibiotic susceptibility of S. aureus 
biofilms under different incubation atmospheres. 
IV. To study the signalling pathways in the gut microbiota-brain axis, and whether 
perturbations of the gut microbiota by antibiotic treatment early in life could 
potentially affect the developing brain. 
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3 PAPERS & DISCUSSION 
3.1 PAPER I - CLASSIC REACTION KINETICS CAN EXPLAIN COMPLEX 
PATTERNS OF ANTIBIOTIC ACTION 
The pharmacodynamics of antibiotics have been difficult to predict and have therefore 
hindered the rational design of antibiotic treatment strategies. Among the major 
complications in predicting antibiotic activity during treatment are: the post-antibiotic effect, 
the inoculum effect and the formation of persister cells. All three phenomena are poorly 
understood and could lead to suboptimal treatment outcomes. In this collaborative study, we 
clearly show that the kinetics of antibiotic killing, when assessed taking into account the 
concentrations of antibiotic and microorganism, are predictive of the in vitro observed 
pharmacodynamics. The significance of this study lies in the a priori assumption of chemical 
kinetics driving the interaction between drugs and target with cell death as readout.  
We first employed a microfluidic approach, where single E. coli cells were exposed to sub-
inhibitory concentrations of tetracycline. In these experiments, cells were allowed to grow for 
4 h on rich medium, and then subjected to sub-MIC concentrations of tetracycline for 16 h 
and their replication was monitored in the post-antibiotic phase for 4 h. A model was used to 
fit this data and it succeeded in reproducing the observed pattern of post-antibiotic effect, 
suggesting that the kinetics of antibiotic-target binding are sufficient to explain this effect. 
Moreover, our model also predicted that slower bacterial growth rates are associated with a 
stronger post-antibiotic effect. 
We then sought to investigate the impact of density-dependent antibiotic effects. In order to 
test the predictive power of the developed model, we used data from batch cultures of E. coli 
and Vibrio cholera exposed to five and six antibiotics, respectively. From the batch cultures, 
we concluded that antibiotic activity reduced with increasing bacterial density in all bacteria-
drug combinations (albeit at different extent). Our model -based on the assumption that 
antibiotic molecules are not an unlimited resource- managed to reproduce this effect. 
Previous studies trying to describe the declining killing efficacy observed in in vitro time kill 
assays have attributed the invariable pharmacodynamic profile to cellular persistence and a 
stochastic switch. We found that of the five antibiotics we tested, there was a strong 
correlation between persistence and antibiotic concentration for streptomycin and 
ciprofloxacin. In vitro time kill experiments validated these results, and we additionally used 
published clinical data from in vivo treatments to investigate further the validity of our model. 
Again, we noted concentration-dependent persistence. This demonstrated that our model, 
based on chemical kinetics alone could account for multiphasic kill curves as well as 
concentration-dependent persistence. 
The developed mathematical model was able to predict the challenging phenomena described 
above and provide an alternative hypothesis for why antibiotic killing slows down over time; 
declining concentrations of free target and/or available antibiotic show strong correlation to 
the experimentally observed situation for all drugs and species considered. In addition to this, 
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we showed that the inoculum effect was also predictable for different drugs and species, as 
well as the duration of the so-called post-antibiotic effect.  
 
3.2 PAPER II - STATIONARY PHASE PERSISTENCE IN STAPHYLOCOCCUS 
AUREUS IS DRIVEN BY BIOFILM FORMATION 
While much work has been done on the susceptibility of exponentially grown cultures of  
S. aureus, stationary phase has remained underexplored. The effects of antibiotics on these 
older, denser and slow growing cells are quite diverse when compared to those of their 
exponentially growing counterparts. In this study we seek to determine whether the 
physiological state of the bacteria affects their susceptibility to six clinically relevant 
antibiotics and to what extent.  
To ascertain this, we examined the contribution of media and stationary phase physiology to 
in vitro estimates of antibiotic efficacy. Having established that extended culturing times lead 
to gradual alkalification of the medium, with adverse effects on antibiotic efficacy, we opted 
to perform our time kill assays on fresh medium. Moreover, we adjusted the bacterial 
densities of the differentially aged cells and exposed them to antibiotics at similar densities to 
avoid any inoculum-related effects. 
Differentially aged cultures (exponential, 1-, 3- and 7-day old) were exposed to six clinically 
relevant antibiotics (ciprofloxacin, daptomycin, gentamicin, linezolid, oxacillin and 
vancomycin) in order to study whether culture age has an effect on antibiotic refractoriness. 
Our results clearly demonstrated that older cultures were significantly more refractory than 
young ones to all six antibiotics. Moreover, the observed refractoriness showed strong age-
dependency. 
We then tested for growth-dependent effects on susceptibility, since bacterial susceptibility is 
tightly intertwined with metabolism and growth kinetics. To that end, we used carbonyl 
cyanide m-chlorophenyl hydrazone (CCCP), a known proton motive force decoupler. We 
reported that for five (linezolid excluded) of the antibiotics, CCCP-treated cultures were 
significantly less susceptible when compared to their respective control cultures. 
Interestingly, linezolid exhibited increased efficacy in the presence of CCCP. 
Long-term culture resulted in increased biofilm formation. Consequently, the contribution of 
biofilm formation to the relative refractoriness was evaluated. Biofilm-residing cells were 
released by sonication and exposed to the same panel of six antibiotics. As with planktonic 
cells, refractoriness increased with culture age. Notably, we observed significantly higher 
refractoriness of these erstwhile biofilm-resident cells when compared to their planktonic 
counterparts. 
We investigated whether a flux between the planktonic and biofilm mode of life existed in 
our experimental system. We competed our wild type (WT) strain and a ciprofloxacin-
resistant (R) derivative of it. We performed biofilm formation assays and then removed 
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planktonic cells introducing an “invasive” population, while following dynamic changes in 
the ratios of the WT and R cell numbers. We thus confirmed the existence of a constant flux 
of cells between the biofilm and planktonic mode of life. 
Having ascertained that cultures were increasingly more refractory with age, we sought to 
investigate whether morphological changes -that have been associated with antibiotic 
refractoriness- were evident. From transmission electron microscopy images we analyzed cell 
size and morphology, cell wall thickness, and replication frequencies. In brief, we 
demonstrated that older cultures were enriched in smaller cells with thicker cell walls. Cells 
from younger cultures exhibited signs of active metabolism, while older cells were less 
metabolically active (solely based on ribosomal content) and had more condensed 
chromosomes. 
Next, we explored the contribution of 23 genes that are involved in global regulatory 
networks, metabolism, virulence, cell division, cell wall biosynthesis and biofilm formation. 
In brief, we reported gene expression patterns (agrA, mgrA, sasG, icaA, sarX, rot) consistent 
with a regulatory network that favors attachment in long-term cultures. 
Overall, we showed that refractoriness is progressive, with older cultures being less 
susceptible than younger cultures. Flux from biofilm to the planktonic compartment resulted 
in sustainably refractory cells. We identified biofilm seeding as the primary cause of this 
refractoriness. Our data supports an alternate hypothesis as to the origin of persister cells, e.g. 
erstwhile biofilm-resident cells with retained general antibiotic refractoriness. 
 
3.3 PAPER III - ANAEROBIC CULTURE CONDITIONS AND THEIR EFFECT ON 
THE SUSCEPTIBILITY OF STAPHYLOCOCCUS AUREUS BIOFILMS 
Biofilm-related infections account for approximately 65% of the hospital-acquired infections, 
according to the Centers for Disease Control and Prevention. Biofilms have also been 
strongly correlated with chronic and latent infections. S. aureus is a prominent biofilm former 
and its ability to cause infection has been associated with biofilm formation. Biofilm 
development is Staphylococci has been ascribed to two mechanisms: ica-dependent and ica-
independent. 
The molecular basis of the ica-dependent mechanism is the transcription of the icaADBC 
locus, which is responsible for the production of polysaccharide intracellular adhesin, 
considered a critical component of the biofilm matrix. On the contrary, in the case of ica-
independent mechanism, other surface-related adhesins facilitate biofilm formation (e.g. 
sasG). 
In this study we sought to investigate the role of incubation atmosphere on antimicrobial 
susceptibility of S. aureus to three clinically relevant antibiotics (ciprofloxacin, daptomycin 
and gentamicin). In paper II, we reported that biofilm-released cells were more refractory 
than their planktonic counterparts. Here, we exposed biofilm-derived cells of two major 
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adhesin knockout mutants (ΔicaA and ΔsasG) and recorded their susceptibility under aerobic 
and anaerobic conditions.  
We first assessed biofilm formation on all three strains (WT, ΔicaA and ΔsasG) using a 
microtiter plate assay. We concluded that under anaerobic conditions there is no significant 
difference on biofilm formation. Interestingly, we reported that ΔsasG forms significantly 
more biofilm (23 %) under aerobic conditions. 
Since crystal violet staining is non-specific (binding both matrix and cell components) we 
decided to directly assess the cell density in biofilms. To remove the biofilm-residing cells 
from their embedding matrix we used sonication. Under aerobic conditions, we reported that 
all three strains had similar cell densities. On the other hand, under anaerobic conditions, 
ΔicaA had more than three times more cells embedded in the biofilm structure. 
We then exposed the released biofilm cells to our panel of antibiotics. In brief, we reported 
that aerobic exposure to ciprofloxacin had no effect on the susceptibilities of the three strains. 
However, under anaerobic conditions all strains exhibited enhanced survival. Daptomycin 
exposure under aerobic conditions sterilized WT cultures. Under anaerobic conditions, 
daptomycin exposure was less effective but at a similar level among all strains. For 
gentamicin we reported the highest differences between aerobic and anaerobic conditions (2,5 
log better survival under anaerobic conditions). 
In conclusion, we reported discrepancies between biofilm assessment by crystal violet and 
direct enumeration of cells residing in the biofilm. More importantly, we showed a 
significantly decreased susceptibility of S. aureus biofilm cells under anaerobic conditions to 
three clinically relevant antibiotics.  
 
3.4 PAPER IV - THE BACTERIAL PEPTIDOGLYCAN-SENSING MOLECULE 
PGLYRP2 MODULATES BRAIN DEVELOPMENT AND BEHAVIOUR 
A growing number of studies have revealed that the gut microbiota can modulate brain 
development and behavior; however, our understanding of the molecular mechanism(s) 
governing these interactions is still limited. In this collaborative study, we investigated the 
translocation of bacterial peptidoglycan from the gut and its impact on the developing brain. 
First, we set to test whether peptidoglycan could be translocated in the blood under normal 
conditions. We found that the peptidoglycan levels in the serum of germ-free mice were 
significantly lower when compared to specific pathogen-free mice. Then, we investigated if 
bacterial peptidoglycan could cross the blood brain barrier and showed evidence of such 
translocation. The next step was to investigate the levels of peptidoglycan in three different 
brain regions (prefrontal cortex, cerebellum and striatum) from mice at various postnatal ages 
(1, 3, 5, 7, 14, 21 and 60 days). We reported an age-dependent increase in peptidoglycan 
levels for all three tested brain regions. No significant differences were found between male 
and female mice, suggestive of sex-differences not being a confounding factor. 
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Having ascertained that peptidoglycan from the gut microbiota can be translocated through 
blood circulation to the developing brain, we sought to investigate the expression profiles of 
peptidoglycan sensing molecules in the striatum by qRT-PCR during these early stages of 
development. We focused on the expression profiles of two specific pattern-recognition 
receptors, which have been reported previously to recognize peptidoglycan; peptidoglycan-
recognition proteins (Pglyrp1, Pglyrp2, Pglyrp3 and Pglyrp4) and the NOD like receptors 
(Nod1 and Nod2). Moreover, we investigated the expression of Toll-like receptor 2, Tlr2 (that 
recognizes peptidoglycan and other components of microbial origin) and peptide transporter 
1, PepT1 (that has been shown to efficiently translocate peptidoglycan fragments). 
We reported that all four peptidoglycan-recognition proteins were expressed in the 
developing brain during specific temporal windows of postnatal development. Pglyrp1 
expression gradually increases reaching a peak at 14 postnatal, while afterwards decreases to 
adult levels. Pglyrp2, Pglyrp3 and Pglyrp4 on the other hand, were significantly more 
expressed during the first days of life and showed a steady decline in expression with age. A 
direct comparison of the expression profiles between male and female mice showed 
significant sex differences. The gene expression levels of Nod1 were significantly lower early 
in life, when compared to adult and had a peak at 21 days postnatally for both sexes. On the 
contrary, Nod2 gene expression showed a gradual increase with age for both sexes. Tlr2 and 
PepT1 mRNA levels were highest at the first day of life and declined over time.  
The gene expression of the all target genes was also assessed in the prefrontal cortex and 
cerebellum. For Pglyrp2, Pglyrp3, Pglyrp4, Tlr2 and PepT1, the expression profiles showed a 
similar pattern. Interestingly, more profound sex differences were noted in the prefrontal 
cortex, followed by the cerebellum and the striatum. The expression of Pglyrp1, Nod1 and 
Nod2 showed brain regional differences and strong sex differences. In summary, the above 
results indicate the existence of an age-, region- and sex-specific manner by which the gut 
microbiota can influence brain development. 
We then decided to evaluate whether manipulation of the gut microbiota could influence the 
expression profiles of the peptidoglycan sensing molecules in the developing brain. Two 
experimental approaches were employed: germ-free mice and pregnant mice that were 
exposed to ampicillin during the last week of gestation and first 3 days post-partum. A 
comparison of the expression profiles between the two models (and their respective controls) 
indicated that several peptidoglycan-sensing molecules are responsive to perturbations of the 
gut microbiota. 
Furthermore, the specific role of Pglyrp2 was investigated, due to its specific function, high 
expression levels early at life and sensitivity to microbiota manipulations. Our results 
suggested that its deletion changed synapse-related gene expression and exhibited a strong 
sex-dependent variance. Juvenile Pglyrp2 knockout mice were subjected to an array of tests 
to assess exploratory activity, anxiety and social behavior. Collectively the results from the 
behavioral studies signified that Pglyrp2 modulates the development of social behavior. 
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In summary, this publication provides evidence that peptidoglycan sensing by specific pattern 
recognition receptors could be one of the signaling pathways mediating the communication 
between the gut microbiota and the developing brain. 
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4 FUTURE PERSPECTIVES 
Microbial research has long been focusing on single species, with most of the knowledge we 
have today coming from mono-species studies. Though convenient for in vitro studies, 
bacteria rarely ever exist as single species in natural settings. Different species with 
completely different metabolic profiles and/or lifestyles can reside together, with biofilm 
seeming to be the most preferred mode life of a given polymicrobial community.  
The implication of biofilm-related infections, as discussed earlier, shows that they are one of 
the major impediments to healing and enables the chronicity of such infections 214. Within an 
infection, biofilm formation is an important barrier to an effective treatment. To complicate 
this scenario further, though unsurprising, there is speculation of persister cells also residing 
in biofilms 78,215,216. 
Resistance of biofilms to antibiotics has at times been attributed to poor penetration of the 
drug and the inability to physically access all cells residing in its depth 217. More recent 
studies, however, provide strong evidence that biofilm matrix does not explicitly restrict 
diffusion of antibiotics through it 218. It has alternatively been suggested that the matrix may 
instead act primarily as a barrier for larger components of the immune system such as 
macrophages and neutrophils 36,219. 
The understanding that established infections form a rather complex and dynamic ecological 
milieu is becoming more prevalent. This milieu would often include different species, 
growing under suboptimal conditions and constantly competing for space and resources. 
Adding biofilm formation and an intrinsic rate of persister formation amongst the different 
species in the community only serves as an approximation to the problem. Superimposed 
upon all the above is the host immune response (with its interacting components), which is 
yet to be accounted for. Taken together, the scenario described above reveals a need for a 
deeper understanding of these communities in the site of infection. Only when the forces that 
govern the ecological relation(s) of the interacting species are elucidated, we can proceed and 
discuss a successful therapeutic regimen.  
 
 
 
 
“The possession of knowledge does not kill the sense of wonder and mystery. There is always 
more mystery”  
Anaïs Nin 
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of all, thank you for sharing your knowledge with me and giving me the chance to work with 
you in the lab. I know the fields of neuroscience and microbiology have “evolved” separately, 
but you saw a convergence point and this odd cross-disciplinary view of yours is what 
amazes me. You have always been supportive, patient and understanding. I have truly 
enjoyed discussing science and life in general with you. I want to express my gratitude for 
your help and support when I needed them the most. I only wish we had had the chance to 
collaborate in more projects. May, thank you for accepting to be my co-supervisor even 
before formally meeting me. We may have not interacted as much as originally planned, 
however, whenever I needed anything you were there for me. Thank you for that. 
To my group members (former and present). First (before everyone else!), Eva; I am again 
short of words here! You helped and inspired me more than any person I have ever worked 
with. There were times we could understand each other with just a look. I think the saddest 
day in my lab life was when you told me that you are leaving the group. I was a bit upset 
(why deny it!) at first, but only for a few weeks. Deep inside I was happy for you! I still 
remember your first week in KI, when you asked me if I take coffee breaks and I replied 
something like: “I don’t usually take breaks”. You had the funniest/confused face ever! You 
have been an amazing lab mate, understanding and caring. I was amazed at your resolution 
when faced with challenges. You have always tried to improve yourself and everyone around 
you. You are by far and with no doubt the one only person I would love to be lab mates 
forever! You will also forever be my qPCR mentor!!! Paulina, what a force of nature you 
are! I think every lab needs a crazy (only with the good meaning) Polish person like you in 
their roster. You work hard and party hard. I am extremely happy to have met you and 
worked with you. You are smart, fast learning and a delight to work with. You always have a 
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smile in your face and problems do not exist for you. You sometimes thought your jokes 
were inappropriate, but I tell you I did laugh a lot! You are a special person and I am positive 
you will find your way. I have faith in you! Ymke, thank you for being such a fantastic 
colleague. You were the second PhD student to join the group and I still remember the 
positive impression I got after your final interview with Klas. You were thrown in deep water 
but you learned very fast how to “swim”. You organized most of the lab logistics making 
everyone else’s life much easier. I enjoyed working as much as having off-work lunches with 
you. I think both Eva and I were worried about you in the beginning but you proved us 
wrong! I hope the future will bring what you want of it ;) Björn, it has been a great 
experience to work and talk with you. We discussed both work and life and I was amazed 
with your views. You are a very realistic person and I think that’s the quality I liked the most 
about you. You helped me with my bioinformatic explorations and I only wish I had more 
time to learn from you. I will always appreciate those long Friday lunches with the group! It 
is such a pity you are not around anymore. Karolina, always with a smile on your face, you 
made every day in the lab a little sunnier. I still remember when you tried to pass on your 
bioinformatics knowledge in 30 minutes on a late Friday evening. I hate to admit, most of it 
went over my head... Thank you for trying to establish fika with homemade cakes! It was fun 
working with you in the lab and I hope the high school microbiome project takes off. 
Omneya and Pilar, the newest additions in the group, I wish you good luck with your 
projects. We met in a very stressful point of my PhD (finalizing manuscripts and balancing 
home life with a newborn). I hope I haven’t been too mean to you! I have enjoyed chatting 
and hanging out in the kitchen with both of you. Daisy, it has been an absolute delight 
sharing the lab with you. I still cannot understand where you get all this never-ending energy! 
I think you are the hardest working person I have ever worked with. You always had a smile 
on your face and you made friends in seconds. You were also the person to introduce me to 
the 12 pm lunch, not because I was hungry but because it was “socially proper”. Joanna, by 
far my favorite master student! I had great laughs with you in the lab and I really missed you 
when you left! Eric, you introduced me to microfluidics. I only wish this project had took off. 
You were in the group for a short time but I still miss the long philosophical conversations we 
had. Joanna R, I certainly enjoyed helping you set up your sequencing runs. You are a hard 
working person with resolution and great determination. Problems are only there to be 
solved! I enjoyed our long discussions in the office and the kitchen. I know your defense is 
also near and I believe you’ll do great. Ellie, my colony-counting angel! I think I would be 
still counting plates without you! I really really appreciate your help! Emma, the most 
formally dressed young person I have ever met. I will never forget the long (and outrageously 
fun) discussions with the rest of the gang (Paulina, Björn and Ellie). It has been very fun to 
have you in the office. 
To all the people in the Medical Nanoscience Center where I started my PhD journey (if I 
don’t write names it is certain I won’t be forgetting anyone!). Thank you all for accepting me 
in the “KI family”! Special mention to Bjorn Hogberg’s group, such a loud and happy crowd! 
Alan, Ferenc, Joao, Erik, Giulio, Esther, Cosimo and Ioanna, you adopted me in every 
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social event. It was great fun to be around you all! Those late after work evenings playing 
games are among my nicest memories. Ben, the first microbiologist to join the corridor after 
me, it has been a great pleasure (and relief) discussing my experiments with you. You always 
had all kinds of suggestions to improve every experiment I had trouble with. Discussing 
science over a beer (or two) has never been more fun. 
To all the people in Stockholm University, with whom I spent the last stretch of my PhD. 
Sunil, Hanna, Gabriela, Raquel, Sara, Jacob, Sushil and Nele. I thank you for all the 
exciting presentations and inspiring discussions. You all made my transition to SU so much 
easier! All of you helped me in various ways (showing me equipment, explaining routines, 
critically discussing my results, and so much more!) and I am very grateful to each and every 
one of you. Sunil, the lab wizard. Every singe time I asked you something, you always came 
up with a comprehensive answer. I believe you will be a very successful group leader. 
Hanna, you were always with a big smile and eager to help. Gabriela, a nature enthusiast 
that always had a positive and supporting word to say. Raquel, sorry I “stole” your desk! I 
will particularly remember your relevant feedback after every presentation. Sara, thanks for 
all you help and all the discussions we had during lunch. Jacob, despite the little time we 
interacted you were always helpful. Sushil, thanks for always having a smile in your face 
whenever we met. Nele, I am particularly grateful for all the discussions we had while 
leaving late from the lab. I might have missed three or four trains on the process, but it was 
simply so effortless discussing with you. From life to science and back to life I believe we 
thought alike on so many levels. Themis, a stressed and scared master student at first, a 
confident PhD candidate now. I am happy you decided to apply for that position. I will 
always remember the fun discussions we had when we bumped into each other in the 
corridor. You made every day in the lab something to look up to; I expect great things of you! 
Yeneneh, you have been the nicest person I have met in a long time. Always with a smile, 
never complained about a single thing and full of hope. Thanks for being such a great 
colleague and caring about everyone! A very special mention to Beatriz, the superhero of 
DMB. You are the one that keeps everything together around there. You solved every 
problem in a blink and seemed to anticipate anything we could ever need. Always happy, 
with a big smile in your face and a kind word for (almost) everyone. You are surely going to 
be missed! I will kindly remember our conversations in a mix of Spanish, Swedish and 
English. You are an angel! 
To other people I worked together with: Pia, thank you so much for giving me the 
opportunity to work with you. Thanks for the fun, informal and productive meetings in KI, it 
was great to have your support. You are a kind and hard working person. When you discuss 
your work you have a spark that captivates. It is inspiring to attend your presentations. Thank 
you for all the help while preparing my defence. Tim, it has been a great pleasure to 
collaborate with you. Exchanging knowledge in microbiology and neuroscience has been fun. 
Thank you for your help and support when I needed it. Best of luck with your future plans. 
Claudio, it has been fun to work together. Discussing movies and games while doing science 
   35 
is the best past time for long incubation periods. Thanks for buying me a beer the day I got 
stranded in Stockholm. I know your defence is soon so I wish you the best of luck! 
To my friends: Belen, I remember meeting you in the queue of a hostel in the distant 2010. 
Since then you have been the third most important member of my Swedish family! I cherish 
all the trips we took, all the alcohol we consumed, all the songs we sung (with our terrible 
voices), all the videogames (TAKE COVER!!!) we played and possibly every moment we 
spend together. Special mention to PPP nights, especially the ones with the bad (very bad) 
movies. We lived together, we partied together, we cried and laughed together, we shared 
special moments. You have my unconditional love! Amigos para siempre (sung by Los 
Μanolos). To my two favorite Americans: Olof and Lexi. I wish I could introduce you to 
each other one day. I envision epic and endless conversations over every possible topic. Olof, 
you have been a great friend since the beginning of our master studies. I cannot even recall 
how we met. However, you are a person I admire and think greatly of. I was quite sad when 
you first moved to Lund and later to Korea. We shared beautiful moments with great 
conversations, epic laughs and endless dinners. I wish one day we live close enough so you 
can take little Alex to forest adventures. Miss you a lot! Lexi, I don’t know if I have ever told 
you, but I think you are a very special person. I am proud of you for choosing to do 
something that truly makes you happy. I will always smile with your “call me” gesture (and 
NO there is no other meaning in it!). I deeply enjoyed our long conversations and the Belgian 
beers we shared. You were a great addition in the office and I hated it when you left. I am 
very happy you enjoy were you are now. I sincerely hope we keep in touch. Magda & Tom, 
I will never forget all the special moments we spent during our master time. I sincerely 
missed you when you moved to Stockholm. I believe you are both great people and I hope we 
keep in touch for the years to come. Heidur & Fabio, best of luck with the newest member 
that is about to join the family! You are both great people and amazing hosts. I really look 
forward to common play dates.  Edda & Ari, thank you for being so close friends to Arancha 
and me. Little Björk is lucky to have you as parents. I hope we continue with our Sunday 
brunch tradition for the years to come. Enrique & Lena, I hope you move to Uppsala and we 
get to spend more time together. You are both very fun people to be around! Enrique, I will 
always remember fondly the hidden energy that you channeled when you tried to rip off gift-
wrappings during the Christmas games! Maria & Tonia, we met through friends that are no 
longer part of our lives. However, this did not stop us from becoming close friends. Thank 
you for taking care of our plants and little Alex (more occasions will appear in the future in 
case you were worried!). We have to agree on a new poison of choice, since this will be the 
last year with tsipouro reserves. Maria, you are a star! I couldn’t be happier for you! Stavros 
& Valia, thank you for being such good friends! We have enjoyed multiple game nights and 
meals. And now a special rule: carrying the thesis with you in game nights gives you each a 
permanent +2 in munchkin fights and reciting a part of it by heart a +5 (usable only once!). 
Looking forward to summer barbeques! Eleniki, that will be your name forever now in my 
book! We shared some great dinners, laughs and tears. We surely missed you when you left 
for Ireland and then to Canada. I hope the future will find us in a closer geographical 
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proximity. Vasso, even though you returned to Greece we still miss you here! Best of luck to 
you and little Stratos. The munchkin gang is missing you! Patricia & Arnold, I think we first 
got together due to our common love for board games, but we kept hanging out because we 
enjoyed each others company. You are very dear friends and a great couple. If we are lucky, 
one day we might live in the same place and our kids get to become best friends! A kiss to 
Miri and Alexander. Mikaela, my first ever Swedish friend! We met in a crazy corridor and 
we partied a lot with that crazy bunch. You will forever have a special place in my heart. I 
sincerely believe that you and Stian are an awesome couple and I look forward to your 
wedding. Elina A, we met in Guides a million years ago! I remember I had just started 
studying biology and you were super interested in following the same path. I am happy you 
did and I am even happier you managed to do so well! I remember one day I was at your 
place and your mother (that had just met me) said that I had been you mentor and inspired 
you to follow that path. I felt utterly embarrassed and proud at the same time. I don’t think I 
did influence your choices that much but it felt special to hear such kind words. Best of luck 
in your future ventures. Elina & Panos, I could write pages over pages for both of you, but I 
will try to keep it short and express my gratitude in person and uncensored! You have been 
my chosen family since the beginning of times. Elina, I could recite endless events from our 
lives that I am grateful you were there to support me or offer a comforting hug. We literally 
grew up together and even though we hated each other at our teens, you are the only person 
(that is no direct family) that I care so deeply about. You have a heart of pure gold and I can 
only feel lucky to call you my friend. You are a special person and you deserve the best! 
Nevertheless, I will never ever forget you did not invite me to your wedding. Never. Ever. 
Πάνο, να ξέρεις ακόµα απορώ πως την αντέχεις αυτή τη φίλη µου! Είσαι ήρωας!!! Έχετε και 
οι δυο την άπειρη αγάπη και υποστήριξη µου. Μπορεί να είµαστε (σχετικά) µακρυά αλλά 
είστε πάντα δίπλα µου! Είσασταν το καλύτερο δώρο που πήρα ποτέ! Περιµένω µε 
ανυποµονησία τα ανηψάκια!! 
An exceptional THANK YOU is in order for a special few that hold a very dear place in my 
heart. I know I haven’t been (lately) the best friend to all of you, but you have all been with 
me in key moments of my life and nothing will make me forget that. Δηµήτρη Γιαννάκη, 
άρχοντα των ελληνικών δρόµων. Γνωριστήκαµε το 1997 (πέρασαν κιόλας 20 χρόνια;;;) στον 
οδηγισµό. Αν θυµάµαι καλά γίναµε φίλοι λόγω της κοινής «συµπάθειάς» µας για το ΤΤΞ. 
Μετά απο αυτό µοιραζόµασταν για πάντα την ίδια σκηνή. Δεν ξέρω αν στο είπα ποτέ αλλά 
ήσουν ο καλύτερος φίλος των παιδικών και εφηβικών µου χρόνων. Κάναµε τρέλλες 
(θυµάσαι το ένα ποτάκι στην Πάτρα µε το σµαρτάκι; το σιχαµερό πιτόγυρο στα Καλάβρυτα; 
το ταξίδι στη Θεσσαλονίκη µε το φορτηγό; τις βόλτες στο Ξυλόκαστρο; τα καρναβάλια στην 
Πάτρα;), κυνηγήσαµε κορίτσια σε όλη την Ελλάδα και ζήσαµε στιγµές ανεπανάληπτες. 
Γελάσαµε, κλάψαµε και χτίσαµε µια φιλία που για µένα είναι αξέχαστη. Θυµάµαι τους 
επικούς καβγάδες για τη διαφορετική µουσική που µας άρεσε. Προσπαθώ να θυµηθώ αν 
ποτε καβγαδίσαµε για κάτι άλλο και δεν µου έρχεται τίποτα. Μπορεί να χαθήκαµε όταν 
έφυγα για τη Σουηδία αλλά όταν σκέφτοµαι τους αγαπηµένους µου πίσω στην Ελλάδα είσαι 
πάντα εκεί! Καλά και ασφαλή χιλιόµετρα φίλε! Πέτρο Κανέλλο, φίλε καλέ, φίλε τρελλέ και 
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τρισµέγιστε ταξιδιώτη! Γνωριστήκαµε σε ένα αµφιθέατρο του µαθηµατικού ίσως και στην 
πρώτη διάλεξη ποτέ. Έχοντας 2 χρόνια παραπάνω ήσουν ο «παππούς» της παρέας µα ήσουν 
και η τρελλή καρδιά της. Άπειρες βόλτες µε το φοκούλι, σαλατούλες στα Friday’s, συνέδρια-
εκδροµές σε όλη την Ελλάδα. Μπορεί να µέναµε σε αντιδιαµετρικές περιοχές µα αυτό δεν 
υπήρξε ποτέ εµπόδιο να βρεθούµε και να διασκεδάσουµε. Η φοιτητική ζωή µου ήταν πολύ 
καλύτερη εξαιτίας σου. Ταινίες, δείπνα, παντοµίµες (λούκου µάδες µε µέλι), συζητήσεις, 
σουβλάκια (πολλά σουβλάκια), ποτάκια σε µια καλοκαιρινή Αθήνα, βόλτες, κρέπες, ταξίδια, 
σινεµά. Τι να πρωτοθυµηθώ!!!! Είσαι ένας σπάνιος άνθρωπος και παρόλες τις δυσκολίες 
πάντα είχες ένα τεράστιο χαµέγελο και µια τεράστια καρδιά. Χαίροµαι που πήγες το πρώτο 
σου ταξίδι στο εξωτερικό µαζί µου. Εκείνο το 3ήµερο στο Λονδίνο ήταν ίσως το πιο 
αυθόρµητο ταξίδι όλων των εποχών (µε την ίζιπεφτ!!). Μερικοί άνθρωποι δεν είναι κοντά 
σου αλλά πάντα µες στην καρδιά σου. Ελπίζω να καταφέρουµε επιτέλους να συναντηθούµε 
κάπου στην Ευρώπη! Αµαλία Κουζώφ, η αγαπηµένη µου grande ψωνάρα όλων των εποχών. 
Γνωριστήκαµε πραγµατικά σε µια κατασκήνωση στις Πρέσπες, αν και για να πούµε την 
αλήθεια είχαµε γνωριστεί µια χρονιά νωρίτερα σε ένα 3ήµερο για στελέχη (λίµνη 
Πλαστήρα;). Για κάποιο λόγο όλοι οι κοινοί µας γνωστοί δε σε συµπαθούσαν, µα όταν 
γνωριστήκαµε κολλήσαµε για τα καλά. Μπορεί στην αρχή να µε ζάλισες µε το «που είναι η 
κατασκευή για το πλύσιµο πιάτων» αλλά εκείνο το µαγείρεµα µε καµµιά 50αριά µπούτια 
κοτόπουλο θα µείνει στην ιστορία (θυµάσαι το κριτσικάκι;). Δε θα ξεχάσω ποτέ εκείνη τη 
βραδυά µετά από ένα ατελείωτο συµβούλιο, αρχίσαµε να µιλάµε και µας βρήκε το ξηµέρωµα 
σε ένα παγκάκι µε τις καρδιές µας ανοιχτά βιβλία. Δε θυµάµαι την παραµικρή λέξη απο 
εκείνη τη βραδυά αλλά θυµάµαι εµάς αγκαλιά να βλέπουµε την ανατολή πάνω από τη λίµνη 
σαν να έχουν ξεφορτωθεί όλα τα βάρη από την ψυχή µας. Αξία ανεκτίµητη! Να ξέρεις ακόµα 
κουβαλάω µαζί µου την αφιέρωσή σου από εκείνη την κατασκήνωση. Ελπίζω πλέον µετά 
από ένα χαλαρό ποτάκι να ξέρεις πως να φορέσεις το µπουφάν σου. Σε αγαπώ! Μαρία Ιω 
Ακαλέστου, θα µπορούσα εύκολα να γράψω σελίδες για σένα. Σπάνια στη ζωή  συναντάς 
ανθρώπους µε τη δική σου σοφία. Ειλικρινά στύβω το µυαλό µου να θυµηθώ που και πως 
γνωριστήκαµε. Νοµίζω το είχαµε συζητήσει στο παρελθόν και καταλήξαµε οτι είχαµε 
γνωριστεί στης Τσιµπούκη (της Ειρήνης!), σε µια εκπαίδευση, σωστά; Θυµάµαι τις βραδιές 
στη Δροσιά µε σουβλάκια και ταινίες, µε µουσική και κρασί, µε συζητήσεις µέχρι το 
ξηµέρωµα. Δεν ξεχνώ πως για πρώτη φορά είδα όλους τους τίτλους τέλους ταινιών µε 
κάποιον άλλο. Δεν ξεχνώ εκείνο το φρικτό σιντί µε το πιάνο. Μου έδωσες βιβλία, µουσική 
και σοφία (τα καλύτερα δώρα που πήρα ποτέ!). Κατά καιρούς µου έδωσες σηµειώµατα µε 
αποφθέγµατα, να ξέρεις τα έχω όλα µαζί µου στη Σουηδία. Νοµιζω γνωριστήκαµε σε 
κοµβικά σηµεία της ζωής µας (...και ξαναβάλεις τις ρόδες µου σε ράγες και εγώ αρχίσω να 
κυλάω, να κυλάω, να κυλάω ξανά). Όταν ένιωσα χαµένος ήσουν εκεί να µου κρατήσεις το 
χέρι και µε ενα γλυκό χαµόγελο και λόγο πήρες τον πόνο µου µακρυά. Μου έδωσες τόσα 
πολλά και για πάντα θα αναρωτιέµαι αν κατάφερα να σου δώσω κάτι πίσω. Η αγάπη είναι 
πολύ µικρή λέξη για να χωρέσει αυτό που νιώθω για σένα. 
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To a special microbiologist and dearest friend, Despoina Lymperopoulou. I never got the 
chance to completely express my gratitude to you, so I choose to do it here. You were my 
first true mentor. You introduced me to microbiology and your passion in your work made 
me love it too! You taught me so many things that without them I wouldn’t be where I am 
now. Skills I learned from you are still with me. You have been the best teacher a student 
could have. I am deeply grateful for that! 
To my Spanish family: Arancha, Ramon, Adrian, Berta, Iñigo y Guille. Hemos pasado 
muchas estupendas vacaciones juntos. Siempre intentais enseñarme cosas nuevas y me llevais 
a un montón de sitios. Si soy honesto, tengo que decir que muchas veces me habeis tratado 
incluso mejor que mi propia familia! Arancha siempre habla sobre vosotros con palabras de 
afecto y cariño. Me parece increíble lo cercanos que sois entre todos y cómo podeis pasar 
horas y horas hablando por Skype. Arancha os quiere a todos incondicionalmente y sois una 
gran parte de su vida. La distancia entre vosotros pesa enormemente sobre ella.  
To my family in Greece. Στην οικογένειά µου. Στον παππού µου Χρήστο και στη γιαγιά µου 
Διάνα, χωρίς εσάς δε θα είχα ποτέ καταφέρει τόσα πολλά. Με στηρίξατε, µε συµβουλέψατε 
και µε αγαπήσατε άνευ όρων. Με υποστηρίξατε στα όνειρα µου και µε προσγειώσατε όταν 
πετούσα στα σύννεφα. Είσασταν, είστε και θα είστε οι «κολώνες» της ζωής µου. Χωρίς εσάς 
δε θα ήµουν ο άνθρωπος που είµαι σήµερα. Στη µητέρα µου Αθηνά, που θυσίασε τόσα 
πολλά για να κυνηγήσω το ονειρό µου. Η αγάπη σου και υποστήριξή σου µε βοήθησαν να 
φτάσω ως εδώ. Πάντα είχες την υποµονή να ακούς τις γκρίνιες µου και να µε συµβουλεύεις 
να δρω µε λογική και όχι συνάισθηµα. Είσαι πάντα δίπλα µου. Στη θεία µου Άρτεµις, µπορεί 
να είσαι στην άλλη άκρη της γης αλλά πάντα ήσουν στο πλευρό µου. Στον ένα µήνα που 
είµαστε µαζί κάθε 3-4 χρόνια, µου δίνεις συµπυκνωµένη όλη την αγάπη που δεν µπορείς να 
µου δώσεις από το τηλέφωνο. Miss you! Στο θείο µου Γιάννη (“βλάκας”), στον άνθρωπο 
που µε έβγαλε για το πρώτο µου ποτό, µε πήγε σε συναυλίες, που προσπαθησε να µε µάθει 
να οδηγάω µηχανάκι και γενικά προσπάθησε να µε κάνει cool από geek. Είσουν ο µεγάλος 
αδερφός που δεν είχα ποτέ. Πρόσεχε τον ευατό σου γιατί βασίζοµαι σε σένα να γεράσουµε 
µαζί. Στη θεία µου Δωροθέα, που µε αγάπησε και εµπιστεύτηκε σα δικό της ανήψι. Στα 
ξαδερφάκια µου Χρήστο και Γιάννη, που για πάντα θα είναι τα παιδιά που άφησα στην 
Ελλάδα πριν σχεδόν 8 χρόνια. Κάθε φορά που σας βλέπω έχετε µεγαλώσει τόσο πολύ. Μέσα 
µου στεναχωριέµαι που δε ήµουν εκεί να σας δω να µεγαλώνετε αλλά ξέρω πως η υπόλοιπη 
οικογένεια σας προσέχει. Ελπίζω να µη συνεχίσετε να βγάζετε το λάδι των γονιών σας! 
And last but definitely not least, Arancha. How can words describe what I feel about you? 
You have been next to me in every single second of this journey. It is simply impossible to 
express the amount of gratitude I have for you. You shared my joy in moments of success, 
you picked me up in moments of failure, you guided me through dark paths, you lifted me 
when things seemed lost and you were always there for me. Your beautiful smile and your 
super hugs were the things to look for after long hours in the lab. Your love has no limits and 
I am the luckiest person on earth to have you by my side. You complete my life in ways I 
could never express. The addition of Alexaki to our team has been one of the happiest 
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moments of my life. It is amazing how someone so small can mean so much for me! I don’t 
know if you will follow your parents’ path in science but my only advice to you is: Do 
whatever makes you happy! Arancha & Alexaki you are my North Star(s). 
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